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ABSTRACT 
Tricyclic antidepressants and beta-adrenergic antagonists lave 
been shown to alter lyiphocyte function in vitro and in vivo* These 
studies were designed to characterize tricyclic antidepressant and 
beta-adrenergic drugscell membrane interactions that nay be related 
to drug-induced alterations of lynphocyte function and growth. 
A single population of specific, high affinity tricyclic 
antidepressant (desipramine) binding sites has been identified on 
murine splenic lynphocyte membrane fragments. The binding is 
saturable, competitive, reversible, and does not display 
interactions characteristic of cooperativity. There are 
approximately 300 binding sites per cell and the apparent affinity 
constant (K̂ ) for the binding site is approximately 0.4 nM. The 
presence of a specific tricyclic antidepressant binding site on the 
lymphocyte suggests a possible mechanism through which these 
compounds may alter lynphocyte function. 
The tricyclic antidepressants (desipramine, iiidpramine, 
nortriptyline, and protriptyline) have been shewn to inhibit 
lymphocyte mitogenesis in a concentration- and time- dependent 
manner. Concentrations of tricyclic antidepressants which inhibit 
lynphocyte mitogenesis half maximally (approximately 10 jiM) f 
however, . are much greater than the apparent for the specific 
tricyclic antidepressant binding site. These results indicate that 
tricyclic antidepressant induced inhibition of lynphocyte 
mitogenesis is not mediated by the specific tricyclic antidepressant 
binding site. 
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In a manner similar to the tricyclic antidepressants , the beta-
adrenergic antagonists (propranolol f alprenolol, metoprolol, and 
sotalol) inhibit lymphocyte mitogenesis at concentrations much 
greater than the apparent for the specific beta-adrenergic 
binding site on the lymphocyte. The beta-adrenergic antagonists 
alter (as determined by fluorescence spectroscopy in this study) 
lynphocyte membrane structure at concentrations that are similar to 
beta-adrenergic antagonist concentrations that inhibit lynphocyte 
mitogenesis. In additionr beta-adrenergic antagonist induced 
alterations of membrane structure and inhibition of lyirphocyte 
mitogenesis parallel the apparent lipophilicity of beta-adrenergic 
antagonists. Beta-adrenergic antagonist-induced alterations of 
membrane structure were found to occur without apparent alterations 
in cell surface receptor mobility or membrane permeability changes. 
Fluorescence spectroscopic techniques have also been used to 
demonstrate tricyclic antidepressant-induced perturbations of 
lymphocyte membranes in a concentration- 9 time-, and temperature-
dependent manner. The concentrations of tricyclic antidepressants 
that perturb lymphocyte membranes are similar to tricyclic 
antidepressant concentrations that inhibit lymphocyte mitogenesis. 
Since the membrane perturbations were suspected to originate in the 
phospholipid bilayer , liposomes were used to characterize tricyclic 
antidepressant drug interactions with single and double component 
phospholipid bilayers. Tricyclic antidepressant-induced alterations 
in two component liposomes can be produced at tricyclic 
antidepressant concentrations that inhibit lymphocyte mitogenesis 
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and perturb lynphocyte membranes* 
In conclusion, tricyclic antidepressants have been shown to 
interact with specific tricyclic antidepressant binding sites on the 
murine splenic lymphocyte. The tricyclic antidepressants also 
inhibit lymphocyte mitogenesis but at concentrations imich greater 
than the for the specific binding site. These results suggest 
that tricyclic antidepressant-indnced inhibition of lympbxyte 
mitogenesis is not mediated by the specific binding site. Results 
from fluorescent spectroscopic studies indicate that the beta-
adrenergic antagonist and tricyclic antidepressant concentrations 
that perturb lymphocyte membrane structure are similar to the beta-
adrenergic antagonist and tricyclic antidepressant concentrations 
that inhibit lymphocyte mitogenesis. Further, beta-adrenergic 
antagonist lipophilicity is related to beta-adrenergic antagonist 
alterations of lymj±iocyte mitogenesis and lyiphocyte membrane 
structure. Also perturbations of the phospholipid bilayer of 
liposomal membranes fcy tricyclic antidepressants occur at tricyclic 
antidepressant concentrations that alter lynphocyte mitogenesis and 
lyirphocyte membrane structure* The results of these studies 
demonstrates the importance of nonspecific drug:cell membrane 
interactions which may be important in the determination of the 
biological activity of these two classes of compounds. 
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INTRODUCTION AND STATEMENT OF PURPOSE 
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INTRODUCTION 
Understanding the basic interactions between drugs and cell 
membranes is of considerable interest and importance in 
pharmacology. While many drugs have specific sites of action on the 
cell membrane, receptors, many drugs are capable of altering 
membrane properties or function through non-specific or non-receptor 
mediated mechanisms. In this regard, it is relevant to determine 
how a cell recognizes the wide variety of drugs to which it may be 
exposed, and how membrane-dependent interactions might result in the 
alteration of cell function. 
The tricyclic antidepressants and the beta-adrenergic 
antagonists are frequently used therapeutic agents. In general, 
agents within these drug classes interact with cell membranes 
through both specific binding sites and non-specific mechanisms. 
The pharmacology of the specific and non-specific tricyclic 
antidepressant drug:cell membrane interactions is not clear. In 
contrast, the specific mechanism of beta-adrenergic antagonist:cell 
membrane interactions (beta-adrenergic receptor blockade) has been 
clearly defined. Yet, like the tricyclic antidepressants, the 
nature of the non-specific beta-adrenergic antagonist:cell membrane 
interactions remain poorly characterized. The fact that both 
tricyclic antidepressants and beta-adrenergic antagonists alter 
lymphocyte responsiveness in vivo and in vitro is relevant to 
pharmacology and immunology. It is of interest, then, to 
characterize previously undefined specific and non-specific 
tricyclic antidepressant and beta-adrenergic antagonist interactions 
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with the cell membrane of the lymphocyte. 
To provide the background upon which this dissertation is 
based, the remainder of the introduction will include general 
overviews of the following subjects: 1) pharmacology of the 
tricyclic antidepressants? 2) pharmacology of the beta-adrenergic 
antagonists; 3) the lymphocyte and neurohumoral receptors; 4) model 
membranes; and 5) probes for investigating drug-membrane 
interactions. The statement of purpose concludes the introductory 
portion of this dissertation. 
Pharmacology of the Tricyclic Antidepressants 
mumiwiP i...- - " riiuP îfffl.' " i rrni • —r n MIIWIIII II .111111111 1 . 11 "™ - .1111 r 1 ' ' " - • — • •• - • 
The first tricyclic antidepressant introduced as a clinically 
useful antidepressant was imipr amine (Kuhn, 1958). Development of 
the tricyclic antidepressants as antidepressants emerged from 
studies in the 19501 s demonstrating that reserpine could produce 
clinical depression in normal persons (Bollister, 1983)• Since 
reserpine depleted biogenic amines in nerve terminals r it was 
postulated that depleted amine levels in the brain might be related 
to depression. Clinical research was then directed at developing 
drugs that increased amine levels in the brain. Subsequently, Kuhn 
(1958) discovered that a structural derivative of the 
phenothiazine, pronoazine, and which is now known as iirdpramine, was 
effective for treatment of endogenous depression. 
The therapeutic effectiveness of imipramine for depression has 
led to the synthesis of chemically related drugs that are conroonly 
used clinically in the United States. Imipramine, a dibenzazepine, 
its major metabolite, desipramine, nortriptyline (an active 
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metabolite of amitriptyline), a dibenzocycloheptadiene, and 
protriptyline, a dibenzoxepine, have been selected as representative 
tricyclic antidepressants for use in the experimental studies of 
this dissertation (Table I). Imipramine possesses a tertiary amine 
group on its aliphatic side chain, while desipramine, nortriptyline, 
and protriptyline possess secondary amine groups on the aliphatic 
side chain. Geometric isomers for these compounds do not exist 
because of the abscence of a center of asymmetry in their chemical 
structures (Baldessarini, 1980). 
Molecular models of the tricyclic antidepressants reveal that 
the most efficacious compounds for treating endogenous depression 
are those compounds with a large angle between the planes of the 
aromatic rings (Maxwell et al., 1969). For example, the angle 
between the planes of the phenyl rings or angle of flexure for 
imipramine is approximately 55°, in contrast to 25° for 
chlorpromazine, a structurally similar compound but of little use 
clinically for treatment of endogenous depression (Finch, 1975). 
Also in contrast to phenothiazine related compounds, the tricyclic 
antidepressants retain biological activity when the N-termninal is 
separated from the ring nucleus by only two carbons (Baldessarini, 
1980). Due to the pKĝ  of the amine group in the aliphatic side 
chains of these compounds (9.5 to 10.5), at pH 7.4, >90% of the 
drugs exist in a protonated, positively charged form. The charged 
form of the tricyclic antidepressants is probably the active 
chemical species in the blockade of amine uptake mechanisms (Maxwell 
et al., 1969). Substitution in the aromatic rings reduces 
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TABLE I 
Tricyclic Antidepressant Structures. 
^ H 3 
Imipramine Desipramine 
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biological activity (Finch, 1975). Unfortunately, the structure-
activity relationships of the tricyclic antidepressants are not well 
understood and the above generalizations may not be applicable for a 
given compound (Baldessarini, 1980; Finch, 1975). 
The tricyclic antidepressants have strong lipophilic 
properties which have been characterized by partitioning in 
immiscible organic solvent-water systems. Imipramine, desipramine, 
and nortriptyline have log octanol-water partition coefficients 
ranging from 4.6 to 4.9 (Frisk-fiolmberg and van der Kleijn, 1972; 
Leo et al., 1971). The log octanol-buffer (pH 7.0) partition 
coefficients for imipramine, desipramine, nortriptyline, and 
protriptyline are also quite similar, ranging from about 1.5 to 2.3 
(Frisk-Holmberg and van der Kleijn, 1972). This lipophilic 
character may contribute to the biological properties of the 
tricyclic antidepressants. For instance, a significant correlation 
between tricyclic antidepressant drug lipophilicity, based upon 
partition coefficients, and histamine release from rat mast cells 
has been reported (Frisk-Holmberg and van der Kleijn, 1972). 
The amine hypothesis of depression is based on the association 
of depression with decreased functional aminergic transmission 
(Garver and Davis, 1979). For a tricyclic antidepressant to be 
effective in treatment of depression, it is considered essential 
that neuronal uptake of monoamines is inhibited (Kostowski, 1981). 
Some pharmacological evidence supports these statements. In fact, 
at least two types of specific tricyclic antidepressant binding 
sites have been associated with the inhibition of the neuronal 
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uptake of norepinephrine and serotonin in the brain and periperal 
tissues (Langer and Raisman, 1983). 
Recently, the hypothesis that the tricyclic antidepressant 
binding site may be related to the therapeutic benefit of these 
compounds has been subjected to some criticism. Sulser (1982) has 
outlined a number of reasons why the amine hypothesis is inadequate 
for describing affective disorders. These reasons include: 1) 
inhibition of neuronal amine uptake by tricyclic antidepressants 
occurs immediately, yet, therapeutic effects are not achieved for 
days or weeks; 2) clinical responsiveness to tricyclic 
antidepressants is seldom uniform despite a uniform inhibition of 
neuronal amine uptake; 3) other effective antidepressants (iprindole 
and mianserin) do not block neuronal amine uptake; 4) cocaine, which 
also blocks norepinephrine uptake, is not an effective 
antidepressant; 5) the failure of other compounds such as 
amphetamine, which possesses properties similar to both MAD 
inhibitors and tricyclic antidepressants, to reverse depression; and 
6) some treatments effective in depression also decrease amine 
levels in the nerve synapses, a finding that is contradictory to 
the amine hypothesis (Sulser, 1982). Results from recent 
experimental studies also indicate that there is no correlation 
between tricyclic antidepressant binding to the specific tricyclic 
antidepressant binding site and the blockade of neuronal amine 
uptake (WDod et al., 1983; Laduron et al., 1982). A more appealing 
mode of action for the tricyclic antidepressants may be the down-
regulation of certain neurotransmitter receptors (Sulser, 1982). 
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Further studies are required to elucidate the true significance of 
the tricyclic antidepressant binding site. 
Despite the lack of knowledge about the mechanism of action of 
the tricyclic antidepressants, they have an established clinical 
usefulness in the treatment of endogenous depression, enuresis, 
chronic pain, and less frequently in obsessive-compulsive-phobic 
states, school phobia in children, minimal brain damage and 
hyperkinesis in children, cataplexy associated with narcolepsy, and 
acute panic attacks (Hollister, 1983). In general, among the 
tricyclic antidepressants, there is little difference in efficacy 
although individual differences may occur. Major adverse effects 
are related to the anticholinergic activity of the tricyclic 
antidepressants and include classical anticholinergic signs such as 
dry mouth, constipation, loss of visual accommodation, and urinary 
hesitancy. Cardiovascular effects are common and include 
palpitation, tachycardia, arrhythmias, orthostatic hypotension, and 
sudden death. Other adverse effects include sedation, confusion, 
weight gain, sexual disturbances, agranulocytosis, and seizures 
(Hollister, 1983). 
Plasma levels of tricyclic antidepressants approach, for 
example, 2.5 uM for imipramine (Perel et al., 1976). These drugs 
are, however, are extensively bound to plasma protein (>90%) and to 
the constituents of tissues and therefore may accumulate in the 
tissues (Baldessarini, 1980; Borga et al., 1969). A more recent 
report demonstrates that concentrations of tricyclic antidepressants 
in the red blood cells of depressed individuals undergoing tricyclic 
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antidepressant therapy are up to six times higher than the plasma 
concentration of tricyclic antidepressants (Linnoila et al., 1978). 
Similarly, a relationship between the tricyclic antidepressant 
levels in the brain tissues and tricyclic antidepressant plasma 
levels exists. The ratio of brain tissue tricyclic antidepressant 
concentration to plasma tricyclic antidepressant concentration is 
40:1 to 8:1 with increasing plasma tricyclic antidepressant 
concentration (Glotzbach and Preskorn, 1982). 
Tricyclic antidepressants are metabolized by two major routes: 
1) transformation of the ring nucleus and 2) alteration of the 
aliphatic side chain. Bydroxylation of the tricyclic ring nucleus 
(at the two or ten position depending upon the compound) followed 
by conjugation with glucuronic acid occurs by the first route, and 
monodemethylation of tertiary amines on the aliphatic side chain 
occurs by the second route. Active metabolites from both routes 
have been described (Hollister, 1983). The half-lifes of these 
compounds range from about 9-24 hours for imipramine to an extreme 
of 54-198 hours for protriptyline (Hollister, 1983). 
Pharmacology of the Beta-Adrenergic Antagonists 
The clinical importance of the beta-adrenergic receptor in the 
cardiovascular disorders such as angina pectoris and arrhythmias has 
resulted in the development of a number of beta-adrenergic receptor 
antagonists. Although dichloroisoproterenol in 1957 (Powell and 
Slater, 1958), was the first beta-adrenergic antagonist discovered, 
propranolol, first introduced and approved for use in 1968, has 
become the most important beta-adrenergic antagonist in clinical 
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medicine (Gothf 1981; Weiner, 1980). A number of beta-adrenergic 
antagonists have since been introduced for clinical use and vary 
from propranolol in their relative effects on cardiac and bronchial 
beta receptors, intrinsic synpathondmetic activity, and membrane 
depressant activity (Goth, 1981? Weiner, 1980). The following 
beta-adrenergic antagonists were selected for use in the 
experimental studies of this dissertation: propranolol, alprenolol, 
metoprolol, and sotalol (Table II). 
The most effective beta-adrenergic antagonists resemble in 
chemical structure, the beta-adrenergic agonist isoproterenol. An 
aliphatic side chain with an isopropyl or bulkier substituent on the 
amine group favors interactions with beta adrenergic receptors. The 
type of substituents on the aromatic ring determines whether or not 
the compound will be an antagonist or agonist, and 
the cardioselective properties of the agent (Weiner, 1980). For 
example, propranolol, alprenolol, and sotalol are non-selective 
beta-adrenergic antagonists while metoprolol is selective for beta 
receptors of the heart (beta-1 receptors). An aliphatic hydroxyl 
group which is required for activity, also gives the drug molecule 
optical activity. The levorotatory (1) form of both beta-adrenergic 
agonists and antagonists is much more potent than the dextrorotatory 
(d) form with regard to drug interactions with the beta receptor 
(Weiner, 1980). The optical activity of the beta-adrenergic agents 
can be used to distinguish between receptor mediated effects and 
non-specific effects of these compounds. The d- and 1- forms of 
propranolol for instance, are approximately equal in potency as 
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TABLE 11 
Beta-Adrenergic Antagonist Structures. 
O C H , — C H O H — C H : N ' H — C H ( C H , U 
Propranolol 
O C H . - C H O H — C : i l . — N H—CH(CH,)., 
C H . — C H = C H , 
Alprenolol 
C ! 1 , - C H ( ) H - ( : H , N H - C H { C H : , I . . , C H O H - C H ^ N H - C H ( C H : I ) 
— CH..OCH3 N H — S O . - C H : , 
M e t o p r o l o l Sofalol 
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local anesthetics, however, d-propranolol is only about 1% as 
effective as 1-propranolol in blocking beta-adrenergic receptors 
(Barrett and Cullum, 1968). 
Beta-adrenergic antagonists competitively antagonize the 
interactions of catecholamines released from adrenergic neurons or 
the adrenal medulla with beta receptors. As a result of beta-
receptor blockade, these drugs exert negative chronotropic and 
inotropic effects on the heart, slow atrioventricular conduction, 
promote bronchoconstriction, lower plasma renin activity, and may 
produce hypoglycemia (Goth, 1981). Some of these drugs may also 
have a quinidine-like or depressant effect on the heart. 
More specifically, the therapeutic effectiveness of propranolol in 
some arrhythmias, for example, may be the result of both beta-
adrenergic receptor blockade and non-specific membrane depressant 
activity (Singh and Jewitt, 1974; Kelliher and Roberts, 1974). 
The non-specific membrane depressant effects of the beta-
adrenergic antagonists are positively correlated to 1iposolubility 
(Dax and Partilla, 1982; Woods and Robinson, 1981; Hellenbrecht et 
al., 1973). Characteristic log octanol-buffer (pH 7.0) partition 
coefficients for propranolol, 5.4, alprenolol, 3.27, sotalol, 0.011 
(Hellenbrecht et al., 1973), and metoprolol, 0.15 (Woods and 
Robinson, 1981), agree favorably with the relative local anesthetic 
or membrane depressant effects of these compounds (Hellenbrecht et 
al., 1973). Further, propranolol and lidocaine are eguipotent as 
local anesthetics (Weiner, 1980). Expressed relative to propranolol 
(1.0), the potency of the beta-adrenergic receptor antagonism ranges 
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from 0*5 - 2.0 for metoprolol, 0*3 - 1.0 for alprenolol, and 0.3 
for sotalol. Therefore, agents possessing less lipophilicity are 
not less effective as beta-adrenergic receptor antagonists (Weiner, 
1980). 
Conroon adverse effects of the beta-adrenergic antagonists are 
referrable to the cardiovascular and respiratory systems, and 
alterations in metabolism (Weiner, 1980). When contractility of the 
heart is impaired, beta-adrenergic antagonists may produce 
bradycardia and reduced cardiac output precipitating congestive 
heart failure. Beta-adrenergic antagonists may also produce 
sensitivity to insulin and oral hypoglycemics. This is due to the 
presence of beta-adrenergic receptors which mediate glycogenolysis 
in muscle and, in some species, glycogenolysis in the liver. In 
patients with comprimised pulmonary function, bronchoconstriction is 
a common side effect of beta-2 and non-selective beta-adrenergic 
antagonists (Weiner, 1980). The central nervals system effects of 
beta-adrenergic antagonists are not conmon but include dizziness, 
depression, hallucinations, nightmares, lassitude, and insomnia 
(Weiner, 1980). 
The plasma concentrations of beta-adrenergic antagonists 
required for control of certain arrhythmias may be quite high* 
Concentrations of d- and 1- propranolol, and alprenolol necessary to 
control ventricular arrhythmias, for instance, may approach 5 fiM 
(Courtney, 1980? Woosley et al., 1977) and 20 jiM (Courtney, 1980), 
respectively. Similar to other lipophilic compounds that are also 
extensively bound to protein, propranolol, for example nay 
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accumulate in tissues such as the heart (Pruett et al.r 1980) and 
brain (Meyers et al., 1975). In the heart, a 40-fold accumulation 
of propranolol has been reported (Pruett et al., 1980) , while a 5 to 
30-fold accumulation in the brain has been reported (Meyers et al., 
1975). A positive correlation, however, exists between the 
logarithm of the plasma concentration of beta-adrenergic antagonists 
and beta-adrenergic receptor blockade. A correlation between beta-
adrenergic antagonist plasm concentration and therapeutic effects 
is harder to establish and may be attributable to inter individual 
variation in plasma protein binding and metabolism (Johnsson and 
Regardh, 1976). 
To some extent, the lipophilicity of the beta-adrenergic 
antagonists is correlated with the extent to which they are 
metabolized. Highly lipophilic beta-adrenergic antagonists like 
propranolol are almost completely metabolized. In contrast, a less 
lipophilic beta-adrenergic antagonist like sotalol is relatively 
unsusceptible to liver metabolism (Johnsson and Regardh, 1976). The 
protein binding of the beta-adrenergic antagonists (propranolol, 
93%; alprenolol, 85%; metoprolol, 12%; and sotalol, little or none) 
also follows the same order as the relative lipophilicity of these 
agents (see above). The elimination half-lifes for these compounds 
are approximately the same ranging from two to four hours for 
propranolol, alprenolol, and metoprolol, and from five to six hours 
for sotalol. These pharmacokinetic parameters will vary in hepatic 
and renal disease states (Johnsson and Regardh, 1976). 
Oxidative deamination and, Odealkylation and oxidation of the 
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side chain, are two common pathways for metabolic transformation of 
beta-adrenergic antagonists* In addition, aromatic and aliphatic 
bydroxylations, and the formation of glucuronic acid conjugates with 
the secondary alcohol group of the aliphatic side chain, are not 
uncommon* Generally three to six metabolites for each beta-
adrenergic antagonist can be identified, but can include as many as 
18 different metabolites, as has been found for propranolol 
(Johnsson and Regardh, 1976)* 
The Lymphocyte and Neurohumoral Receptors 
The immune system is regulated by a complex interplay of a 
number of mechanisms including cell-cell interactions, antibodies, 
lymphokines (Jegosthy, 1978), factors influencing the lymphatic 
microenvironment (Jankovic and Isakovic, 1973), the complement 
system, extracellular electrolytes (Freedman, 1979), and a number of 
other factors such as neurohormones (Mertin and Thcmpson, 1981; 
Strom, 1980). Until recently, the role of the central nervous 
system in the regulation of the immune response has been overlooked* 
It has been demonstrated that iinnunocompetence of man and animals is 
altered in the presence of stress (Riley, 1981) and affective 
disorders (Kronfol et al*, 1983). Studies have also shown that 
there are alpha-adrenergic (Hadden et al*, 1970), beta-adrenergic 
(Johnson and Gordon, 1980), miscarinic-cholinergic (Gordon et al*, 
1978), nicotinics-cholinergic (Richman and Arnason, 1979), 
histaminergic (Rocklin, 1976), and opiate (Bazurrt et al*, 1979) type 
binding sites en the lymphocyte. Results from esgperintental studies 
in in vitro systems would suggest that some of these binding sites 
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may be considered pharmacological receptors (Oilman et al, , 1982; 
Johnson et al., 1981; Dulis et al.f 1979; Hadden et al., 1970). In 
addition, studies with brain-lesioned animals have demonstrated an 
apparent relationship between activity of certain structures of the 
brain, particularly the hypothalamus, and immune function (Mertin 
and Thompson, 1981; Jankovic and Isakovic, 1973). Collectively, 
this evidence indicates that there may be a functional relationship 
between the central nervous system and the iinmune system. Further, 
that neurohormones may function as regulators of the immune response 
through specific neuro-type receptors on the lymphcnsyte. Based on 
similar evidence, Golub (1982) and Mertin and Thompson (1981), also 
proposed the existence of a functional connection between the 
nervous system and the immune system * 
The presence of a specific tricyclic antidepressant binding 
site in various brain regions (Langer et al.r 1981), like the 
neuroreceptors discussed above, and on non-neuronal cells such as 
platelets (Briley et al., 1979) and lung (Raisman and Langer, 1983), 
presents the possibility that there m y tricyclic antidepressant 
binding sites on other non-neuronal cell types such as lymphocytes. 
A lymphocyte tricyclic antidepressant binding site might then be 
implicated in reports that imipramine has been observed to produce 
leukopenia (Leyberg and Denmark, 1959) and reduce elevated 
rheumatoid factor levels (Haydu et al., 1974) in vivo, and inhibit 
mitogenesis (Nahas et al., 1979; Smith et al., 1978; Waterfield et 
al., 1976) and the number of plaque-forming cells (Saith et al., 
1978) in vitro. Tricyclic antidepressant-induced alterations of 
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lymphocyte reponsiveness in in vitro systems have been attributed to 
the non-specific effects of these drugs although direct experimental 
evidence supporting this assumption has not been reported* In in 
vivo studies the possible mechanisms involved in alteration of 
lymphocyte reponsiveness and function by tricyclic antidepressants 
have been suggested to be related to membrane ATPase function 
(Haydu et al*, 1974)* Direct in vitro studies of lynphocyte ecto-
OTPase activity indicate that the tricyclic antidepressants 
selectively alter the enzyme's activity at high concentrations (*1 
to 1 nM) (Medzihradsky et al, 1980)* 
A beta-adrenergic binding site on the lynphocyte has been 
identified. Propranolol, for example, binds to the lynphocyte beta-
adrenergic receptor with an apparent affinity constant (K̂ ) of 10 nM 
(Johnson and Gordon, 1980)* The concentrations of propranolol, 
however, that alter lymphocyte reponsiveness, in vitro, are at least 
1000-fold higher (Johnson et al*, 1981; Anderton et al., 1981; 
Montecucco et al., 1981; Moore et al., 1978; Dunne et al*, 1978) 
than the apparent for the beta-adrenergic receptor on the 
lynphocyte* It is probable, then, that the propranolol binding 
site is not involved in the alteration of lymphocyte responsiveness 
at high concentrations. Propranolol1s non-specific or local 
anesthetic properties have been implicated in altering lynphocyte 
responsiveness and function, although direct evidence in the 
lymphocyte has not been reported. 
The identification of neuro-type binding sites on the 
lynphocyte is important in the pursuit of an understanding of the 
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cell :soluble ligand interactions that may be important in altering 
the immune response. In addition, it is important to consider other 
cell:soluble ligand interactions, such as non-specific mechanisms, 
that may provide information about how the lyirphccyte recognizes and 
responds to different pharmacological agents. Furthermore, an 
understanding of cell:soluble ligand interactions relevant to the 
lyirphocyte may be applicable to cell:soluble ligand interactions in 
general. Cell biologists have long recognized the lyirphocyte as a 
useful model cell for investigations of membrane phenomena that 
extends beyond the scope of immunology (Nfossal, 1978). It is one of 
the few mammalian cells which can be isolated easily, incurring 
little damage in the isolation, do well in culture, and for which a 
significant amount of information about the cell membrane structure 
exists (Nossal, 1978; Resch, 1976; Zuckerman and Douglas, 1976). It 
is for all the reasons above that the lynphocyte was chosen as a 
suitable cell type for the experimental studies of this 
dissertation. 
Model Membranes 
The complex composition of the biological membrane complicates 
the interpretation of drug-membrane interactions. Specific 
molecular interactions of drug with the phospholipid bilayer, for 
example, can not be precisely defined. Phospholipid vesicles, or 
liposomes, provide a relatively simple model membrane system which 
one can use to study drug:phospholipid bilayer interactions 
(Bangham, 1978? Tritton etal., 1977). Liposomes are easy to 
prepare, the composition in terms of polar head group and lipid is 
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known and can be selected, and more importantly, the liposome has 
the same basic phospholipid bilayer structure found in the 
biological membrane (Bangham, 1978; Tritton et al., 1977; Tyrrell et 
al., 1976). Liposomes have been used characterize local anesthetic 
(Papahadjopoulos et al., 1975), opiate (Johnson et al., 1979), 
tricyclic antidepressant (Romer and Bickel, 1979; Bermejo et al., 
1975; Cater et al., 1974; Bermejo et al., 1974), quinidine 
(Surewicz, 1982), and propranolol (Surewicz et al., 1981) 
interactions with phospholipid bilayers. 
Calorimetry, electron spin resonsance, fluorescence 
spectroscopy, and nuclear magnetic resonance techniques have been 
used to study tricyclic antidepressant drug interactions with 
dipalmitoylphosphatidylcholine bilayers (Romer and Bickel, 1979; 
Bermejo et al., 1975; Cater et al., 1974; Bermejo et al., 1974). 
The results of these studies have been interpreted in terms of drug 
interactions with the surface or polar head groups of the 
phospholipid bilayers. Fluorescence spectroscopic studies of the 
ability of these drugs to perturb the structural order of the fatty 
acid chains of the phospholipid bilayer of liposomes have not been 
reported. Therefore, large multilamellar liposomes will be used in 
an experimental study to characterize tricyclic antidepressant drug 
interactions with the lipid domains of liposomes. The phospholipids 
chosen for preparation of liposomes in this study will be 
phosphatidylcholines or lecithins, the most abundant 
phosphoglycerides in animal cell membranes (Chapman, 1968). 
Liposomes prepared from these phospholipids are well characterized 
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(Stubbs et al., 1981; Lentz et al., 1976a; Lentz et al., 1976b; 
Andrich and Vanderkooi, 1976). 
Probes for Investigating of Drug-Membrane Interactions 
Presently, the pharmacologist has a number of membrane probes 
available to explore drug-cell membrane interactions. Obviously, 
the choice of probe depends upon the nature of the drug-cell 
membrane interaction to be studied. It is appropriate at this time 
to discuss the membrane probes applicable to this study that will be 
used to elicit information about the specific and non-specific 
tricyclic antidepressant and beta-adrenergic antagonist:cell 
membrane interactions. 
A large contribution to the current understanding of the 
receptor mediated mechanisms of a wide variety of drugs, hormones, 
and toxins is due in part to the development of reliable ligand 
binding assays (Hollenberg and Nexo, 1981). Providing certain 
criteria are met, precise quantitative data relating to drug-
receptor interactions may be obtained. The radio-labeled ligand 
must: have a high specific radioactivity, be biologically active, be 
used at a temperature that minimizes ligand and receptor 
degradation and permits convenient binding equilibration times, be 
used to study appropriate ligand concentration ranges, and be used 
in a study utilizing a method of separating free and receptor bound 
ligand within a time period appropriate for the ligand off-rate 
(Hollenberg and Nexo, 1981). Two tritium-labeled ligands, 
desipramine and imipramine, are available and considered 
appropriate, under the conditions above, for studying tricyclic 
23 
antidepressant binding sites (Langer and Raisman, 1983). JE-
Desipramine has been chosen as the radio-labeled ligand for 
detecting the presence of specific tricyclic antidepressant binding 
sites on the murine lymphocyte. 
The non-specific interactions of tricyclic antidepressants and 
beta-adrenergic antagonists, similar to those exhibited by local 
anesthetics, have been attributed to the ability of these compounds 
to perturb structural integrity of the biological membrane (Roth, 
1979; Lee, 1976; Seeman, 1972). More specifically, by perturbing 
the structural characteristics of the phospholipid bilayer of the 
cell membrane, these compounds may alter the function of components 
(receptors, enzymes, and ionophores, for example) residing in the 
phospholipid bilayer (Maher and Singer, 1984; Roth, 1979; Metcalfe 
et al., 1974; Sheetz and Singer, 1974; Seeman, 1972). The nature of 
the mechanism involved in drug-induced membrane perturbations, 
however, is not clear. At least four possible drug-tdlayer 
interactions have been suggested as possible mechanisms of action 
for the nonspecific effects of these compounds and include: 1) 
intercalation of the drugs into the phospholipid bilayer (Seeman, 
1972); 2) selective intercalation of the drugs into the two halves 
of the phospholipid bilayer (Sheetz and Singer, 1974); 3) binding of 
the drugs to lipid-protein interfaces within the phospholipid 
bilayer (Metcalfe et al,, 1974); and 4) drug-induced rearrangement 
of lipids and proteins in the plane of the membrane (Maher and 
Singer, 1984). Direct experimental evidence for tricyclic 
antidepressant or beta-adrenergic antagonist drug-induced membrane 
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perturbations, for the roost part, have not been reported. 
A number of techniques are available for studying membranes 
including direct techniques such as nuclear magnetic resonance 
analysis and x-ray diffraction analysis, and indirect techniques 
such as electron spin resonance and fluorescence spectroscopy 
(Levine, 1972)« The direct techniques are perhaps potentially more 
useful, however, due to the complexity of biological membrane 
interpretation of results is difficult. Indirect techniques can 
provide information that is supplemental to direct techniques 
(Vanderkooi and McLaughlin, 1976). 
Fluorescent probes are useful in the study of membranes 
because of the selectivity of the probe for certain membrane 
environments and the sensitivity of the probe to changes in the 
surrounding microenvironment. "When a fluorophore is exposed to 
radiation of proper energy, quanta of energy are absorbed fcy the 
fluorophore causing the electrons to be excited to a higher energy 
state. The equilibrium excited state lasts approximately 0.1 to 1 
nsec. During the excited state, interactions between the 
fluorophore and other molecules in the fluorophore1 s 
microenvironment affect the characteristic fluorescence parameters 
of the fluorophore. Fluorescence parameters that are altered by 
fluorophore-environmental molecule interactions include the spectra 
of excitation and emission, the lifetime of the excited state, the 
quantum yield, and the polarization or anisotropy of the 
fluorescence emission (Vanderkooi and McLaughlin, 1976). 
Diphenylhexatriene (Shinitzky and Barenholz, 1974), a highly 
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lipophilic fluorescent probe has been used to characterize 
alterations of membrane hydrophobic or lipid domains in the presence 
of disease (French et al, 1983; Shinitzky and Inbar, 1974; Inbar, 
1976) , and a number of pharmacologically active agents (Kutchai et 
al., 1980; Johnston and Melnkovych, 1980; Luly and Shinitzky, 1979; 
Johnson et al., 1979). Diphenylhexatriene aligns itself parallel 
to the fatty acid chains in the phospholipid bilayer (Van 
Blitterswijk et al., 1981; Andrich and Vanderkooi, 1976), but does 
not, itself, alter membrane structure (Andrich and vanderkooi, 
1976). Deviation of the diphenylhexatriene molecule from the 
preferential alignment parallel to the fatty acid chains can be 
determined by change in the fluorescence emission in vertical and 
horizontal planes. Fluorescence anisotropy is a relative measure of 
the deviation in the alignment of the diphenylhexatriene molecule 
relative to the fatty acid chains of the phospholipid bilayer 
(Lackowicz, 1983; Van Blitterswijk et al., 1981; Andrich and 
Vanderkooi, 1976). Measurement of the fluorescence anisotropy or 
polarization of diphenylhexatriene provides information then, about 
the structural order of the phospholipid bilayer (Lackowicz, 1983; 
Van Blitterswijk et al, 1981). Further, the fluorescence lifetime 
of diphenylhexatriene is used to interpret fluorescence anisotropy 
or polarization changes as alterations of the structural order of 
the membrane, or as quenching when the fluorescence lifetime is 
decreased (Lackowicz, 1983). 
Diphenylhexatriene distributes preferentially into the 
phospholipids of the lymphocyte with at least 60% of the 
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diphenylhexatriene found in the plasma membrane (Johnson and 
Nicolau, 1977). The fluorescence emission of diphenylhexatriene is 
greatly enhanced in a hydrophobic environment and there are little, 
if any, differences in the partitioning of diphenylhexatriene 
between different lipid phases (Andrich and Vanderkooi, 1976; Lentz 
et al., 1976b). Based on fluorescence and distribution 
characteristics, diphenylhexatriene was chosen as an appropriate 
membrane probe of tricyclic antidepressant and beta-adrenergic 
antagonist interactions with lymphocyte membranes. 
Fluorescein-labeled concanavalin A binds to concanavalin A 
receptors on the cell surface of lymphocytes (Inbar and Sachs, 
1969). The fluorescence polarization of fluorescein-labeled 
concanavalin A has been used to detect differences in the mobility 
of cell surface receptors on normal and malignant lymphocytes (Ben-
Bassat et al., 1977; Shinitzky and Inbar, 1974; Inbar et al,, 1973). 
Since the mobility of cell surface receptors is probably associated 
with changes in the dynamic nature of the phospholipid bilayer (Ben-
Bassat et al., 1977), the use of fluorescein-labeled concanavalin A 
should provide information that is complementary to studies of 
diphenylhexatriene reported membrane perturbations (Shinitzky and 
Inbar, 1974). It is noted that perturbations of the phospholipid 
bilayer by pharmacological agents must apparently be quite large 
before alterations of the mobility of cell surface concanavalin A 
receptors are observed. For example, the movement of concanavalin 
receptors to one pole of the lymphocyte (capping) is inhibited by 
concentrations of propranolol 100-fold higher than propranolol 
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concentrations that inhibit lymphocyte transformation presumably 
through manbrane perturbations (Anderton et al., 1981). 
Dithio-diisopropyl-oxacarbocyanine iodide, a cyanine dye, is a 
fluorescent probe that useful for monitoring changes in the 
transmembrane potential of cells (Waggoner, 1979). This cyanine dye 
molecule possesses a delocalized positive charge and, depending upon 
the transmembrane potential, partitions between extra- and intra-
cellular compartments and the plasma membrane. The exact mechanism 
of action is unknown, though it has been suggested that non-
fluorescent aggregates form when the dye associates with the plasma 
membrane. Association of the cyanine dye with the plasma membrane 
is promoted by hyperpolarization of the transmembrane potential 
resulting in decreased fluorescence emission. Dissociation of the 
cyanine dye from the plasma membrane is promoted by depolarization 
of the transmembrane potential resulting in increased fluorescence 
emission (Bramhall et al., 1976). The fluorescence emission of this 
cyanine dye will be used to monitor the resting transmembrane 
potential of the murine lymphocyte in the presence of different 
pharmacological agents. 
Lectins, proteins or glycoproteins, which stimulate lymphocytes 
to undergo mitosis and transformation through oligosaccharide 
receptors on the lymphocyte membranes, can be used as probes of 
cellular responsiveness (Zuckerman and Douglas, 1976). The 
ability of lectins or "mitogens" (agents that promote mitosis) to 
induce normal lymphocyte transformation is considered to be an in 
vitro correlate of cell mediated iirmunity (Oppenheim and 
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Rosenstreich, 1976) • Mitogen stimulated lynphocytes in a short-term 
culture system have also been used as a model system for 
characterizing the effects of pharmacological agents on the immune 
response (Strom, 1979) . To assess the physiological activity of 
lymphocyte" cell surface-binding sites, for example, the normal 
mitogen response is determined in the presence of relevant 
concentrations of the corresponding ligand* This system has been 
used sucessfully to demonstrate the physiological relevance of 
opiate (Gilman et al*, 1982), nicotinic--cholinergic (Mizuno et al*, 
1982), beta-adrenergic (Johnson et al. f 1981), miscarinic-
cholinergic (Dulis et al., 1979), and alpha-adrenergic (Badden et 
al*, 1970) binding sites. 
Mitogen stimulated lymphocytes are of interest in studying the 
effects of compounds that perturb cell membranes through non-
receptor mediated mechanisms. Upon interaction with a mitogen, the 
lymphocyte undergoes extensive biochemical and morphological 
alterations. In addition to changes in DNA, KNA, lipid, and protein 
synthesis, complex changes in the plasma membrane occur* Seme of 
these changes include the stimulation of glycoprotein and 
phospholipid synthesis and metabolism, uptake of amino acids, 
sugars, cations, phosphate, and an overall increase in the 
permeability of the plasma membrane (Zuckerman and Douglas, 1976) * 
Lipophilic agents such as local anesthetics, beta-adrenergic 
antagonists, and psychotropic drugs, for instance, probably alter 
lymphocytes responsiveness to mitogen stimulation by perturbing the 
phospholipid bilayer of the lymphocyte plasma membrane (Montecucco 
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et al., 1981; Anderton et al., 1981; Nahas et al., 1979). An 
altered lipid bilayer presumably alters the environment of 
components (receptors, enzymes, and ionophores) dissolved in that 
phase to a degree which is incompatible with normal cell activity 
(Maher and Singer, 1984; Roth, 1979; Metcalfe et al., 1974; Sheetz 
and Singer, 1974; Seeman, 1972), Experimental evidence from 
biological membranes to support these assumptions, specifically with 
regard to tricyclic antidepressants and beta-adrenergic antagonists, 
has not been reported. 
The mitogens, concanavalin A, a polyclonal activator of T 
lymphocytes, and 1ipopolysaccharide B, a polyclonal activator of B 
lymphocytes, have been selected for use in the experimental studies 
of this dissertation. 
Statement of Purpose 
The specific and non-specific mechanisms through which 
tricyclic antidepressants may alter lymphocyte responsiveness in 
vitro and in vivo have not been determined. Clearly, imipramine is 
capable of altering lymphocyte responsiveness in vitro (Nahas et 
al., 1979; Smith et al., 1978; Waterfield et al., 1976) and in vivo 
(Baydu et al., 1974; Leyberg and Denmark, 1959). Although tricyclic 
antidepressant binding sites appear to be ubiquitously distributed 
throughout the body on neuronal and non-neuronal cells, the 
identification and characterization of a lymphocyte tricyclic 
antidepressant binding site has not been reported. The presence of a 
specific tricyclic antidepressant binding site on the lymphocyte 
could be implicated as a mechanism through which tricyclic 
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antidepressant drugs might alter the lymphocyte responsiveness. In 
the first experimental study, the presence of a specific tricyclic 
antidepressant binding site on the murine lymphocyte will be 
determined. 
In the second experimental study, the ability of four tricyclic 
antidepressants to alter the normal mitogen response of murine 
lymphocytes will be assayed. Murine lymphocytes will be stimulated 
to undergo mitosis by either concanavalin A or lipopolysaccharide B 
and the concentration- and time- dependency of drug action on 
lymphocyte mitogenesis determined. The results will be compared to 
results in the first experimental study to determine if the 
tricyclic antidepressant binding site on the lymphocyte may have 
physiological activity. 
It is presumed that high liposolubility is associated with the 
ability of a drug to perturb the phospholipid bilayer's structural 
order. Therefore it is appropriate to consider the beta-adrenergic 
antagonists as part of this study based on the large differences in 
apparent the liposolubility of one beta-adrenergic antagonist as 
compared to another. The tricyclic antidepressants, in contrast, 
all have similar apparent liposolubilities. The intent of the 
third and fourth experimental studies is to relate drug-induced 
membrane perturbations to drug liposolubility, and to compare the 
drug-induced membrane perturbations to drug-induced alterations of 
lymphocyte responsiveness. The two classes of compounds provide a 
range of different apparent liposolubities. 
The third experimental study will involve investigation of the 
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the ability of beta-adrenergic antagonists to perturb the membranes 
of the murine lymphocyte. Fluorescent probes will be used to 
monitor the concentration-, time-, and temperature- dependency of 
beta-adrenergic antagonist effects on membrane structural order. 
These experiments will provide experimental support for the 
assumption that beta-adrenergic antagonist-induced inhibtion of 
lymphocyte responsiveness may be associated with drug-induced 
membrane perturbations. 
In the fourth experimental study, fluorescent probes will be 
used to determine the ability of the tricyclic antidepressants to 
perturb murine lymphocyte membranes. The concentration-, time-, and 
temperature- dependency of tricyclic antidepressant-induced 
alterations of membrane structural order will be assayed. These 
experiments will provide experimental support for the assumption 
that tricyclic antidepressant effects on membrane structural order 
can be implicated as a mechanism for tricyclic antidepressant-
induced alterations of lymphocyte responsiveness. 
Tricyclic antidepressant drug interactions with the liposomal 
membranes will be characterized in the fifth experimental study. 
Previous studies, involving a variety of techniques, have examined 
only desipramine or imipramine effects on dipalmitoyl-
phosphatidylcholine or egg-phosphatidylcholine liposomes (Romer and 
Bickel, 1979; Bermejo et al, 1975; Cater et al., 1974; Bermejo, et 
al., 1974). The emphasis of these studies was on drug:polar head 
group interactions. In this study drug:lipid interactions will be 
characterized using the fluorescent probe diphenylhexatr iene. 
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Electron microscopy will be used to determine the size of the 
liposomes. 
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EXPERIMENTAL STUDIES 
PART I 
CHARACTERISTICS OF TRICYCLIC ANTIDEPRESSANT BINDING SITES 
ASSOCIATED WITH MURINE LYMPHOCYTES FROM SPLEEN 
48 
ABSTRACT 
A single population of high affinity, saturable, tricyclic 
antidepressant (̂ Ehdesipramine) binding sites has been identified on 
the membranes of murine lymphocytes. There are approximately 300 
binding sites per cell and the apparent dissociation constant (K̂ ) 
for these binding sites is about 0.4 nM. Competition studies 
between the radiolabeled ligand in concentrations near the and 
other members of the class of tricyclic antidepressants indicate 
that binding is competitive, reversible, and does not display 
interactions characteristic of cooperativity. 
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INTRODUCTION 
Depression is one of the most common emotional disorders 
presented to today's physician. Often this disorder consists of one 
or more syndromes varying in degree of severity and characterized by 
abnormal, sometimes enduring, changes of affect, and physical 
alterations (Linn, 1980). Because of their widespread occurrence, 
the availability and utility of mood elevating drugs in therapy has 
become quite important. The drugs of choice for treatment of 
depressive syndromes of moderate severity are members of a class of 
compounds known as the tricyclic antidepressants (Prazer, 1980). 
While an exact mechanism of action for members of this class has not 
yet been resolved, it is currently presumed that the therapeutic 
action is at least in part a result of the blocking of neuronal 
uptake of norepinephrine and/or serotonin (Kostowski, 1981). 
Recently methods which successfully led to the identification of 
opiate (Pert and Snyder, 1973), benzodiazepine (Braestrup and 
Squires, 1977; Mohler and Okada, 1977), and neuroleptic (Burt et 
al., 1976) binding sites, have been employed to demonstrate that 
specific saturable tricyclic antidepressant binding sites are 
present on the cellular membranes of rat brain (Raisman et al., 
1979; Rehavi et al., 1981; Sette et al., 1981), human brain (Rehavi 
et al., 1980), and human platelets (Briley et al., 1979; Paul et 
al., 1980). 
This study demonstrates the presence of a single population of 
tricyclic antidepressant (̂ H-desipramine) binding sites on the 
cellular membranes of murine lymphocytes. Johnson et al. (1981) 
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have shown the murine lymphocyte to be a useful model of cellular 
responsiveness. Interestingly, the ability of the tricyclic 
antidepressants to alter lymphocyte responsiveness has not been 
reported. One clinical study has reported a correlation of 
autoantibody levels and simultaneous treatment of depression with 
imipramine (Haydu et al., 1974); however, confirming studies of this 
nature have not been reported. The presence of tricyclic 
antidepressant binding sites on murine lymphocytes would provide a 
possible mechanism by which these drugs might alter the immune 
response. 
MATERIALS AND METHODS 
Desmethyl imipramine hydrochloride, (2,4,6,8-%)-, (lot no. 
1433-170, 59.6 Ci/itmol) was obtained from New England Nuclear Corp., 
Boston, MA. Desipramine hydrochloride was a gift from Merrell Dow 
Pharmaceuticals, Inc., Cincinnati, OH. Nortriptyline hydrochloride 
was a gift from Lilly Research Laboratories, Indianapolis IN. 
Imipramine hydrochloride (lot no. 121P-0086) was obtained from Sigma 
Chemical Co., St. Louis, MO. All other compounds used were of the 
highest grade commercially available. Swiss-Webster, LairCox, 
outbred male mice were purchased from Laboratory Supply Company, 
Inc., Indianapolis, IN. 
Lymphocyte Isolation. This procedure has been described by 
Johnson and Gordon (1980). Briefly, adult male mice (25-30 gm) 
were sacrificed, spleens removed and lymphocytes isolated by 
centrifugation. Erythrocytes were lysed with ammonium chloride and 
the final pellet resuspended in distilled water. Lymphocyte 
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membrane fragments were then frozen until used (overnight at -70°C). 
Binding Assay. Membrane fragment suspensions were thawed at 
37°C and then centrifuged at 250 * g for 15 min (18°C). The 
resultant pellet was resuspended in 0.05 M Tris-Cl, pH 7.4. A 
homogenous suspension was prepared by homogenizing with a motor 
driven teflon pestle (8-10) passes. Absence of intact cells was 
ascertained by the lack of trypan blue exclusion. Protocol for the 
binding assay was essentially the same as that used by Johnson and 
Gordon (1980) and is as follows: 0.25 ml aliquots of the membrane 
fragment mixture (0.1 - 0.3 mg protein) were placed in 13 x 100 mm 
test tubes along with appropriate concentrations of competing 
ligands to give a final volume in each assay tube of 0.3 ml. The 
assay was initiated by the addition of the radiolabeled ligand to 
the assay tube. The assay tube was immediately placed in a 37°C 
water bath with gentle shaking for 15 min. After addition of 1 ml 
of cold incubation buffer (0.05 M Tris-Cl buffer, pH 7.4) to 
terminate the assay, contents of the assay tube were rapidly 
filtered through pre-wetted (with 10"^ M desipramine) Whatman GF/B 
filters. The assay tube was rinsed once with 5 ml of wash buffer 
(0.01 M phosphate buffered saline, pH 7.4) and each filter washed 
with 4 x 5 ml of wash buffer. Rapid filtration and washing 
procedures required approximately 15-20 seconds. Filters were air 
dryed then placed in 3.5 ml of scintillation fluid (160 ml of 
Biosolv per 1 liter of LSC Complete, Yorktown Research, Miami, FL) 
and the tritium assayed in a Packard Tri-Carb scintillation 
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spectrophotometer (approximately 58% tritium efficiency) to 0.5% 
accuracy. 
Desipramine binding to lymphocyte membrane fragments was 
determined by addition of 7 * 10"^ to 9 * 10 ~ 8 M desipramine to 
assay tubes either containing no competitor or a competitor of a 
concentration of 10"^ M competitor. Specific binding is the 
difference between total bound and that bound in the presence of 
10"^ M competitor (nonspecifically bound). 
Dissociation Kinetics. Dissociation of desipramine bound to 
lymphocyte membrane fragments was studied by a dilution technique 
described by Krawietz et al. (1980), and Johnson and Gordon (1980). 
A 4 ml aliquot of homogenous mixture of lymphocyte membrane 
fragments was incubated at 37°C for 15 min in the presence of 5 * 
10~^ M ^H-desmethylimipramine. At times specified after the 15 min 
incubation, 0.01 ml of the mixture was added to each of duplicate 
test tubes containing either 10 ml of incubation buffer containing 
no competitor or 10 nil of incubation buffer that was 10 M in 
desipramine. The contents of the dissociation assay tubes were 
rapidly filtered, washed, and counted in the same manner as the 
binding assay tubes. A plot of both dilution displacement and 
dilution displacement in the presence of a competitor was generated. 
Data points were calculated as a percentage of the total bound in 
each set and the results plotted as % Bound (log scale) versus Time. 
All experiments were performed in duplicate or triplicate. All 
protein concentrations were determined by a modified Lowry method 
which included the use of 1% deoxycholate. 
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RESULTS 
The binding of ̂ H-desipramine to murine lymphocyte membrane 
fragments is saturable and of high affinity (Figure 1). The 
concentration of ̂ H-desipramine required to achieve saturation is 
approximately 4 nM. Scatchard analysis (Figure 2) indicates a 
single population of binding sites with an apparent of about .4 
nM. The maximal concentration of binding sites is about 50 fmol/mg 
protein which corresponds to approximately 300 binding sites per 
cell. Specific binding as defined earlier in the text was usually 
10-40% of the total bound. 
Competition studies between ̂ H-desipramine and other unlabeled 
members of the tricyclic antidepressant class were conducted in the 
presence of approximately 3 nM ^H-desipramine. The ability to 
compete for ^H-desipramine binding sites was greatest for 
desipramine (Figure 3), followed by imipramine (not shown) r and 
nortriptyline (Figure 3). Propranolol (not shown) failed to compete 
-10 
for these binding sites over the same concentration range (10 to 
10 ~^ M). The ability of various tricyclic antidepressants to 
compete with %-tricyclic antidepressants at low concentrations has 
been observed previously (Table I) by Rehavi et al. (1981), 
The reversibility and absence of cooperativity for the binding 
of %-desipramine to murine lymphocyte membrane fragments is shown 
by the dissociation curves (Figure 4). The dissociation rate 
constant as determined from the slope is 0.02 min - 1; the calculated 
association rate constant is 4 * 101 M min . 
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Figure 1. Specific binding of %-desipramine to murine lymphocyte 
fragments. Approximately 0.3 mg of membrane protein was incubated 
with increasing concentrations of 3 H-desipramine in a total volume 
of 0.3 ml for 15 min at 37°C. Specific binding was determined as 
described in Materials and Methods. Each point is the mean of 
duplicate determinations. 
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Figure 2. Scatchard Analysis of the specific binding of 
desipramine to murine lymphocyte membrane fragments (about 0.3 
membrane protein). 
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Figure 3. Effect of desipramine (+) and nortriptyline (o) on the 
specific binding of ̂ H-desipramine to murine lymphocyte membrane 
fragments. 
59 
I 
TABLE I 
Comparison of ̂ H-Desipramine Binding Site Characteristics 
% (nM) 
Murine Lymphocyte 0.4 
Rat Cerebral Cortex * 1.4 
Desipramine 
Imipramine 
Nortriptyline 
IC50 (nM)** 
Murine Lymphocyte 
7 
54 
375 
IC50 (nM)*** 
Rat Cerebral Cortex* 
3 
62 
6 
* Rehavi et al., 1981. 
** IC50 represents the concentration required to inhibit 50% of the 
specific binding of ^H-Desipramine (3 nM) to murine lymphocyte 
membranes. 
*** I C 5 0 represents the concentration required to inhibit 50% of the 
specific binding of %-Desipramine (1 nM) to rat cerebral cortex 
membranes (Rehavi et al., 1981). 
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Figure 4. Dissociation of %-desipramine binding to murine 
lymphocyte membrane fragments. • • represents displacement in 
the absence of a competitor, o o represents displacement in the 
presence of a competitor. 
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DISCUSSION 
Binding sites for a radiolabeled tricyclic antidepressant ( ̂  fi-
des ipramine) with the characteristics of high affinity, 
saturability, and which can be competed for by other 
pharmacologically active tricyclic antidepressants have been 
demonstrated on the murine splenic lymphocyte. The results reported 
here are similar to those observed in previous studies using ^H-
desipramine and ^H-imipramine to identify binding sites on the 
membranes of various brain tissues and platelets (Rehavi et al., 
1981; Sette et al., 1981; Rehavi et al., 1980; Paul et al., 1980; 
Raisman et al. 1979; Briley et al., 1979). 
It is well known that the tricyclic antidepressants interact 
with a number of neurotransmitter binding sites including, a -
adrenergic (U'Prichard et al., 1978), muscarinic-cholinergic (Rehavi 
and Sokolovsky, 1978), and histaminergic (Green and Maayani, 1977), 
with high affinity, and are also known to alter 0-adrenergic 
receptor function (Kinnier et al., 1980). These interactions 
correlate well with the known side-effects associated with tricyclic 
antidepressant therapy. It also known that murine lymphocytes 
possess 3 -adrenergic (Johnson and Gordon, 1980), and muscarinic-
cholinergic (Gordon et al., 1978) binding sites. Further studies 
will elucidate whether or not the ̂ H-desipramine is interacting with 
the muscarinic-cholinergic binding site on the murine lymphocyte. 
The absence of cooperativity is suggested by the linear 
Scatchard plot (Figure 2), and the dissociation curves (Figure 4). 
A 100-fold dilution in buffer of ̂ H-desipramine bound to membrane 
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fragments gave an off-rate for ̂ H-desipramine that was equal to an 
off-rate determined from a 100-fold dilution into a buffer 10 in 
desipramine. The rationale for this experiment is that a 100-fold 
dilution of ^H-desipramine lowers the ligand concentration two 
orders of magnitude below the K<j for the ligand resulting in a 
minimal reassociation of ligand to binding site. Cooperative 
effects could be suggested if the off-rate for the dilution in the 
presence of the competitor was different. That isf the latter off-
rate might be slower if cooperativity were involved. The 
interpretation of these results the cooperative interactions are not 
occurring is consistent with the linear Scatchard plot. 
Many of the reports demonstrating the presence of tricyclic 
antidepressant binding sites correlate these findings with the 
physiological action most often attributed to the tricyclic 
antidepressants. That action is the blocking of the uptake of 
norepinephrine and/or serotonin by neurons or platelets (Rehavi et 
al., 1981; Sette et al., 1981; Rehavi et al., 1980; Paul et al., 
1980; Raisman et al., 1979; Briley et al., 1979). Since the murine 
lymphocytes do not appear to be involved in the uptake of either of 
these monoamines, the presence of tricyclic antidepressant binding 
site seems perplexing. However, it is important to recognize that 
not all of the known antidepressants produce their effects through 
this monoamine uptake mechanism (Kostowski, 1981). Although it is 
one of the prominent effects of the tricyclic antidepressants, it is 
probable that not all of the facets of the biochemical events 
occurring in the mechanism of action for the tricyclic 
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antidepressants have been described* Therefore it is possible that 
the tricyclic antidepressant binding site on the murine lymphocyte 
may perform some physiological function that has not been 
delineated* 
The detection of tricyclic antidepressant binding sites on the 
murine lynphocyte presents the possibility that these drugs might 
possess some selective action on the overall immune response* This 
report forms the foundation of future studies to determine if the 
tricyclic antidepressant action on the immune response may manifest 
itself by suppressing or enhancing that response* 
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TRICYCLIC ANTIDEPRESSANT EFFECTS ON THE 
MURINE LYMPHOCYTE MITOGEN RESPONSE 
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ABSTRACT 
Tricyclic antidepressant binding sites have recently been 
detected on the membranes of murine splenic lymphocytes (Audus and 
Gordon, 1982). It is reported here that the mitogen response of 
murine lymphocytes is altered in the presence of tricyclic 
antidepressants at concentrations of 10 or greater. The time-
dependent effects of these drugs, when added to the cultures at 
various times up to 24 hours subsequent to addition of a mitogen 
(either concanavalin A or lipopolysaccharide B), are also reported. 
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INTRODUCTION 
The tricyclic antidepressants are a class of drugs used to 
treat depressive syndromes of moderate severity (Frazer, 1980). The 
exact mechanism of action for these drugs has not been precisely 
defined; however, the current literature supports a hypothesis that 
the tricyclic antidepressants act in part by blocking catecholamine 
and/or serotonin uptake (Kostowski, 1981). 
Recently, a single population of saturable, high affinity 
binding sites were identified on membrane fragments of murine 
splenic lymphocytes (Audus and Gordon, 1982). The presence of the 
tricyclic antidepressant binding site on lymphocytes could provide a 
mechanism through which these drugs might alter the immune response. 
To verify physiological activity of the binding site, a short-term 
culture system in which the physiological response measured is a 
lymphocyte response to a particular mitogen was established. The 
murine lymphocyte system has been used to further characterize the 
immune response, as modified by a variety of pharmacologic agents 
(Strom et al., 1980). 
Previous reports have identified muscarinic cholinergic (Gordon 
et al., 1978), nicotinic (Richman and Arnason, 1979), alpha-
adrenergic (Hadden et al., 1970), and beta-adrenergic (Johnson and 
Gordon, 1980) binding sites on both human and murine lymphocytes. 
The relative importance of identifying these binding sites may be 
illustrated by the recent reports of Davis et al. (1980), and 
Johnson and Gordon (1980), whose observations show that alterations 
of beta-adrenergic binding site sensitivity by chronic 
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administration of beta-adrenergic agents can result in changes of 
human lymphocyte regulation* The implications of these changes in 
the immune response may be of importance to individuals undergoing 
catecholamine treatment for cystic fibrosis aid asthma* The 
detection of a tricyclic antidepressant binding site likewise 
establishes the importance of determining whether or not tricyclic 
antidepressants alter the immune system. 
MATERIALS AND METHODS 
Thymidine (6-^H)-, was purchased from New England Nuclear, 
Boston, MA* Concanavalin A (lot no* 910026) was obtained from 
Calbiochem-Behring Corp* , La Jolla, CA. Lipopolysaccharide B, 
serotype no. 0111:B4 (lot no* 98C-0407) and imipramine HC1 (lot no* 
121F-0086) were from Sigma Chemical Co., St. Louisf MO. Desipramine 
HC1 was a gift from Merrell Dow Pharmaceutical Inc., Cincinnati, OH. 
Nortriptyline HC1 was a gift from Lilly Research Laboratories, 
Indianapolis, IN* Protriptyline HC1 was a gift from Merck Sharp & 
Dohme Research Laboratories, West Point, PA* All other compounds 
used in this study were of the highest grade commercially available. 
Lai :Cox, Swiss-Webster, outbred male mice were pur chased from 
Laboratory Supply, Co., Inc., Indianapolis, IN. 
Lynphocyte Isolation* This procedure has been described in 
detail by Johnson and Gordon (1980)* Briefly, adult mice (25-30 g) 
were sacrificed, spleens were removed aseptically through a flank 
incision, and the lymphocytes isolated by centrifugation* 
Erythrocytes were removed by lysis with ammonium chloride. 
Lyirphocytes were suspended in a final concentration of approximately 
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5 * 10° cells/ml in RPMI 1640 (supplemented with 10% bovine serum, 
100 U penicillin, and 100 |ig streptomycin). Lymphocyte viability, 
as assessed by trypan blue exclusion, was always greater than 92% 
following the isolation procedure. 
Short-Term Lymphocyte Cultures. 0.05 ml of the mitogen (either 
Concanavalin A or Lipopolysaccharide B) in concentrations of 0 to 90 
|j.g/ml, and 0.02 ml of a tricyclic antidepressant solution were added 
to each of 96 wells of a microtiter plate (Model 3040, Falcon 
Division, Becton-Dickinson, Qxnard, CA). 0.1 ml of cell suspension 
was added to each well as the last addition. Imipramine and 
desipramine were dissolved in sterile water (sterile water served as 
the corresponding control), and protriptyline and nortriptyline in 
sterile 0.01 M phosphate buffered saline (PBS), pH 7.4 (PBS served 
as the corresponding control). All solutions added to the culture 
plates were first filtered through 0.22 micron filters (type GS, 
Millipore Corp., Bedford, MA). Incubations were carried out at 
37°C, with 5% CO2 and 95% air. After a 24 h incubation period, each 
well was pulsed with 0.03 ml tritiated thymidine (0.5 p-Ci), bringing 
the total well volume to 0.2 ml. Cells were collected on Whatman 
glass fiber filters with a cell harvester (Model 24V, Brandel, 
Gaithersburg, MD). Filters were allowed to air dry, then were 
placed in scintillation vials with 3 ml of LSC Complete (Yorktown 
Research, Miami, FL) and assayed for radioactivity to an accuracy of 
0.05% in a Beckman Tri-Carb Scintillation Spectrophotometer 
(approximately 58% tritium efficiency). 
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Procedure to Determine the Effects of Tricyclic Antidepressants 
on the Response to Mitogen. Typically, the microtiter plates were 
divided in half, in order that the top half of the plate (4 rows by 
12 columns) could serve as control wells for the remaining wells of 
the plate. The control wells could contain mitogen, cells, and 
either sterile water or PBS only. The remainder of the plate 
received, in addition to the above, various concentrations of drug. 
In some experiments, the concentrations of mitogen was varied over 
the 12 columns. In other experiments, the variable was the drug 
concentration or time of addition of the drug. In the latter case, 
these drug additions occurred at times 0, 1, 4, 8, 12, and 24 h. 
The addition of the mitogen and cells to the plate defines time 0. 
Results from the bottom portion of the plate were compared with the 
corresponding controls obtained from the top half of the plate. On 
occasion, the relationship was expressed as a ratio of incorporated 
counts (Modified Stimulation Index: MSI). 
Statistical Analysis. Results of the mitogen dose-response 
curves, as altered by tricyclic antidepressants, are expressed as 
means + or - the standard deviation of quadruplicate samples. The 
statistical method of error propagation was applied to results where 
the MSI was calculated (Bevington, 1969). 
RESULTS 
The four tricyclic antidepressants tested suppressed the normal 
mitogen response of the murine splenic lymphocytes when the drug 
concentration was 10"-5 M or greater. Figures 1 and 2 are 
representative of the typical response observed for each of the 
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tricyclic antidepressants when the final drug concentration was 10 $ 
M and 10 °M, respectively. Greater than a 90% suppression of the 
mitogenic response was observed at 10 for all four compounds, 
while only partial suppression was observed when the concentration 
was 10"-5 M. Any suppression or enhancement of the response is 
absent at concentrations less than or equivalent to 10"^ M. 
The suppressive effects of the tricyclic antidepressants were 
comparable when 1 ipopolysaccharide B (LPS B; a B-lymphocyte specific 
mitogen) was introduced rather than concanavalin A (a T-lymphocyte 
specific mitogen). Each of the four tricyclic antidepressants 
produced greater than 90% suppression of the mitogen dose-response 
at a final concentration of 10 " ^ M while only partial suppression is 
observed at 10 ~$ M. Little or no suppression of the mitogenic 
response at a final concentration of 10"^ M is observed for any of 
the tricyclic antidepressants tested. Figures 3 and 4 are 
representative of the effects of the tricyclic antidepressants on 
the LPS B dose-response curve. 
In the above experiments the time of addition of the drug was 
time 0. Drug addition subsequent to time 0 resulted in an 
attenuation of the observed suppression. Figure 5 represents a 
typical time dependent decrease of the suppression observed for all 
four compounds in the presence of an optimal doese of concanavalin A 
(2.5 ug/ml). In another series of timed addition experiments, a 
significant change in the degree of suppression was observed when 
the concentration of the mitogen was greater than optimal. Figures 
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Figure 1. Modulation of the Concanavalin A dose-response by 10 "^M 
desipramine. Murine splenic lymphocytes were added to each well of 
a microtiter plate set up as detailed in Materials and Methods. 
Control wells (+) are compared to experimental wells (o) which 
received 10 desipramine. A resultant point is the mean of four 
determinations + or - the standard deviation. 
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Figure 2. Modulation of Concanavalin A dose-response by 10 M 
desipramine. Murine splenic lymphocytes were added to each well of 
a microtiter plate set up as detailed in Materials and Methods. 
Control wells (+) are compared to experimental wells (o) which 
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received 10 M desipramine. A resultant point is the mean of four 
determinations + or - the standard deviation. 
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Figure 3. Modulation of Lipopolysaccharide B dose-response by 10 _ : ; 
M nortriptyline. Murine splenic lymphocytes were added to each well 
of a microtiter plate set up as detailed in Materials and Methods. 
Control wells (+) are compared to experimental wells (o) which 
received 10 M nortriptyline. A resultant point is the mean of 
four determinations + or - the standard deviation. 
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Figure 4. Modulation of the Lipopolysaccharide B dose-response by 
10"^ M nortriptyline. Murine splenic lymphocytes were added to each 
well of a microtiter plate set up as detailed in Materials and 
Methods. Control wells (+) are compared to experimental wells (o) 
which received 10 ~^M nortriptyline. A resultant point is the mean 
of four determinations + or - the standard deviation. 
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6 and 7 compare mitogenic suppression observed at drug addition time 
0 with that observed drugs addition at 12 h and 24 h in the presence 
of 10 nortriptyline. 
DISCUSSION 
This study was designed to determine if the recently identified 
tricyclic antidepressant binding site on murine splenic lymphocytes 
might provide a mechanism through which tricyclic antidepressants 
could alter the immune response. To investigate the possiblity that 
the binding site may possess this physiological function, a series 
of short-term culture experiments were conducted using four common 
tricyclic antidepressants (desipramine, imipramine, nortriptyline, 
and protriptyline). The murine lymphocyte mitogen response in a 
short-term culture system has been shown to be a useful model of the 
immune response (Wedner and Parker, 1976). Each drug was 
subsequently tested for the ability to alter the normal lymphocyte 
mitogen response. 
Results of the culture experiments indicate that all four 
tricyclic antidepressants have similar effects on the normal mitogen 
response. A concentration of 10"^ M effects almost complete 
suppression of the mitogen response. While 10~^M drug results in 
partial suppression, a ten-fold lower concentration failed to effect 
suppression. This observation, when considered in view of the 
apparent Kd of 4 * 10 ~ 1 0M for the tricyclic antidepressant binding 
site, suggests the possibility that the effects of concentrations of 
tricyclic antidepressants greater than 10"-̂  M may not be mediated by 
this high affinity binding site. 
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Figure 5. Modulation of the optimal dose of Concanavalin A by 
additions of 10 ~^M and 1 0 M imipramine at various times up to 24 
h after time 0. Murine splenic lymphocytes were added to each well 
of a microtiter plate set up as detailed in Materials and Methods, 
The MSI for results of the 10 M imipramine addition (o) axe 
compared to the results of the 10 "^imipramine addition (+), A 
resultant point is the ration of mean incorporated counts with drug 
present/mean incorporated counts without drug (control). A mean is 
calculated from quadruplicate wells. The method of error 
propagation has been applied in determination of the standard 
deviation for the MSI, 
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Figure 6. Modulation of the Concanavalin A dose-response by 10"^M 
nortriptyline added 12 hours after time 0. Murine splenic 
lymphocytes were added to each well of a microtiter plate set up as 
detailed in Materials and Methods. Control wells (+) are compared 
to experimental wells (o) which received 10 ~$ M nortriptyline 12 
hours after time 0. A resultant point is the mean of four 
determinations + or - the standard deviation. 
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Figure 7. Modulation of the Concanavalin A dose-response by 10"-5 M 
nortriptyline added 24 hours after time 0. Murine splenic 
lymphocytes were added to each well of a microtiter plate set up as 
detailed in Materials and Methods. Control wells (+) are compared 
to experimental wells (o) which received 10 nortriptyline 24 
hours after time 0. A resultant point is the mean of four 
determinations + or - the standard deviations. 
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In contrast, the recently identified beta-adrenergic binding 
site on the murine lymphocyte possesses an apparent Kfl which 
correlates well with the concentrations of beta-adrenergic agonists 
necessary to suppress the mitogen response (Johnson et al., 1981; 
Johnson and Gordon, 1980). Similarly, the muscarinic binding site 
exhibits an apparent Kd as determined by direct binding studies 
which correlate with cholinergic agonist concentrations known to be 
physiologically active (Dulis et al., 1979). 
The physiological function most often associated with the 
tricyclic antidepressant binding site of the CNS and platelet is the 
blocking of catecholamine and/or serotonin uptake (Lee and Snyder, 
1981; Rehavi et al.r 1981; Sette et al., 1981; Rehavi et al., 1980; 
Paul et al., 1980; Briley et al., 1979; Raisman et al., 1979). 
While such a function has not been ascribed to lymphocytes, this 
does not preclude the possibility that the tricyclic antidepressant 
binding site may be involved in other biochemical or physiological 
activities on the lymphocyte, platelet, and in the CNS. 
Results of the time addition of tricyclic antidepressants to 
the short-term cultures indicate that the drugs are effective in 
suppressing the concanavalin A response when added up through 12 h 
after time 0. All four of the drugs tested were equally effective 
in concentrations of 10 "^M and 10"^ M. Studies of the mouse 
splenic lymphocyte response to concanavalin A have indicated that 
there may be two crucial time periods (the first 0-3 h and a second 
15-18 h after time 0) during which it is necessary for the 
concanavalin A to interact will cell surface receptors and deliver 
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signals initiating mitogenic events. Providing both signals are 
received, mitosis will occur about 48 h after time 0 (Toyoshima et 
al., 1976). These signals can be interrupted by certain drugs 
resulting in suppression or prevention of mitosis. Beta-adrenergic 
agonists when added to the lymphocyte cultures are effective only if 
added within 1 h post time 0 (Johnson et al., 1981). Later 
additions of beta-adrenergic agonists to the cultures have no 
effect, suggesting that the beta-adrenergic may interfere with 
events involved in the first signal period. The tricyclic 
antidepressants appear capable of altering mitotic events at the 
time of, and after, the first signal period (0-3 h after time 0). 
The tricyclic antidepressants are not apparently able to effect a 
large suppression, however, if added after the second signal period, 
15-18 h after time 0. From these observations it may be concluded 
that the mitotic events occurring after the second signal period are 
relatively unsusceptible to the disrupting effects of the tricyclic 
antidepressants. 
The reduced mitogen response of lymphocytes exposed to high 
concentrations of concanavalin A has been assumed to be analogous to 
high antigen dose tolerance (Wedner and Parker, 1976). The 
lymphocytes exposed to high concentrations of concanavalin A enter 
into an entirely reversible, unresponsive state for the duration of 
the 48 h culture (Andersson et al., 1972). In our experiments the 
concentrations of tricyclic antidepressants of 10"^ M or greater 
sharpened the concanavalin A dose-response curve. The degree of 
sensitivity of the mitogen dose-response curve to different 
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concentrations of tricyclic antidepressants appeared greater at 
higher concentrations of concanavalin A. The significance of this 
observation is that the tricyclic antidepressants appear to 
accentuate the high antigen dose attenuation of the mitogen 
response. 
In summary, the tricyclic antidepressants are capable of 
suppressing the mitogen dose-response at concentrations of 10" ̂  M or 
greater in a time-dependent manner that may be related to the two 
signal period hypothesis. In addition, the tricyclic 
antidepressants may magnify the effects of higher concentrations of 
concanavalin A on lymphocyte response according to the suggested 
high dose tolerance model. Finally, the results indicate that the 
inhibitory effects of the tricyclic antidepressants on the immune 
response is probably not mediated by the recently identified high 
affinity binding site. 
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EXPERIMENTAL STUDIES 
PART III 
USE OF FLUORESCENT PROBES TO MONITOR PROPRANOLOL 
EFFECTS ON THE MURINE SPLENIC LYMPHOCYTE 
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ABSTRACT 
Recent studies indicate that propranolol suppresses the normal 
murine lymphocyte mitogen dose-response (Johnson et al., 1981) and 
that propranolol has a high affinity for the beta-adrenergic binding 
site on the murine lymphocyte (Johnson and Gordon, 1980). Since 
concentrations which suppress the lymphocyte mitogen dose-response 
are much greater than the for the binding site, it may be 
suggested that the suppression of the mitogen dose-response is a 
result of nonspecific effects of propranolol. Three fluorescent 
probes (l,6-diphenyl-l,3,5-hexatriene (DPH), fluorescein conjugated 
concanavalin A (F-Con A), and 3,3'-dithio-diisopropyl-
oxacarbocyanine iodide (diS-C3-(5)) were used to investigate 
possible mechanisms of the nonspecific effects of propranolol on the 
murine splenic lymphocyte. 
This report presents data which suggests a possible 
relationship between propranolol concentrations that alter lipid 
membrane dynamics, as monitored by the fluorescence polarization of 
DPH, and suppression of the mitogen dose-response in short term 
cultures as effected by propranolol. Also reported are effects of 
propranolol on the relative mobility of surface membrane lectin 
receptors as monitored by the fluorescence polarization of F-Con A, 
effects of propranolol on the transmembrane potential as monitored 
by the fluorescence emission of diS-C3-(5), and the propranolol 
effect on the fluorescence polarization temperature-dependence of 
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DPH and F-Con A. Studies of the effects of sotalol, alprenolol, and 
metoprolol are included and used for comparison of different drug 
effects» 
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INTRODUCTION 
Propranolol is a nonspecific beta-adrenergic antagonist that 
has found clinical utility in the treatment of certain cardiac 
disease states. Recently, propranolol, at concentrations of 10 uM 
or greater, was shown to suppress the normal mitogen dose-response 
of murine lymphocytes in a short term culture system (Johnson et 
al., 1981). Additionally, propranolol appears to prolong the time 
to rejection of heart-lung allografts in the rat (Larson et al., 
1982). It has also been demonstrated that propranolol binds with 
high affinity (K^ = 10 nM) in a competitive manner to the murine 
lymphocyte beta-adrenergic binding site (Johnson and Gordon, 1980). 
Since concentrations that resulted in suppression of the normal 
mitogen dose-response are significantly greater than the K^, it is 
probable that suppression of the mitogen dose-response is due to 
non-receptor mediated (nonspecific) effects of propranolol. Further 
evidence for suppression of the mitogen dose-response is derived 
from the observation that d- and 1- isomers of propranolol are 
equally effective, at concentrations of 10 uM or greater, in 
suppressing the mitogen dose-response (Johnson et al., 1981). 
Three fluorescent probes, DPH, F-Con A, and DiS-C3-(5), have 
been used in this study to investigate the interactions of 
propranolol with the murine lymphocyte. DPH is a lipophilic 
fluorescent probe used to measure relative changes in the dynamic 
nature of the hydrophobic regions of cellular membrane. Monitoring 
the polarization of DPH has been used for investigation of the 
effects of a number of drugs including anesthetics (Pang et al., 
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1979), steroids (Shinitzky and Inbar, 1974; Johnston and 
Melnykovych, 1980), alcohols (Kutchai et al, 1980), tumor promoting 
agents (Fisher et al., 1979), hormones (Luly and Shinitzky, 1979), 
and opiates (Johnson et al., 1979) on changes in fluidity of live 
cells or artificial membranes. DPH has also been used to 
differentiate between normal and abnormal cells (Inbar, 1976; 
Shinitzky and Inbar, 1974). The polarization of F-Con A bound to 
cell surface Concanavalin A (Con A) binding sites has been used a 
monitor of the mobility of the Concanavalin A binding site and the 
dynamic characteristics of the cell membrane surface of normal and 
abnormal cells (Ben-Bassat et al., 1977; Inbar et al., 1973). DiS-
C3-(5) is a fluorescent dye that exhibits differences in 
fluorescence emission as it partitions between intra- and 
extracellular compartments. The partition of diS-C3-(5) between 
intra- and extra- cellular compartments is altered by changes in the 
transmembrane potential (Waggoner, 1979) of the lymphocyte. Results 
with other beta-adrenergic antagonists, sotalol and alprenolol, and 
a selective beta-l-adrenergic antagonist, metoprolol, will be used 
for comparison with the results observed for propranolol. 
This report demonstrates the ability of propranolol, which is 
much more lipid soluble than most beta-adrenergic compounds (Dax and 
Partilla, 1982; Woods and Robinson, 1981), alter the relative 
dynamics of the hydrophobic regions of the murine lymphocyte cell 
membrane. The alteration of the relative hydrophobic dynamics by 
propranolol occurs in a concentration range that is similar to the 
concentration range required for its suppressive effect on the 
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normal lymphocyte mitogen dose-response. These observations along 
with those for the other beta-adrenergic compounds tested, appear to 
be consistent with recent reports assessing the liposolubility of 
various beta-adrenergic compounds (Dax and Partilla, 1982; Woods and 
Robinson, 1981). 
MATERIALS AND METHODS 
1,6-Diphenyl-l,3,5-hexatriene was purchased from Molecular 
Probes, Inc., Piano, TX. Fluorescein conjugated Concanavalin A (F-
Con A; fluorescein/protein (molar): 4.9) and Concanavalin A (Con A) 
were purchased from Calbiochem-Behring Corp., La Jolla, CA. Dithio-
diisopropyl-oxacarbocyanine iodide (diS-C3-(5)) was a gift from 
Professor Alan Waggoner, Amherst College, Amherst, MA. Propranolol 
HC1 and Histopaque-1077 were purchased from Sigma Chemical Co., St. 
Louis, MO. Sotalol HC1 was a gift from AB Hassle, Fack, S-431 20 
Molndal, Sweden. Metoprolol was a gift form CIBA Pharmaceutical 
Co., Summit, NJ. RPMI1640 was obtained from Grand Island Biological 
Company (Gibco), Grand Island, W. Swiss-Webster, Lai:Cox, outbred 
white male mice were purchased from Laboratory Supply Company, Inc., 
Indianapolis, IN. All other compounds were of the highest grade 
commercially available. 
Lymphocyte Isolation. Briefly, adult male mice (25-30 g) were 
sacrificed by cervical dislocation and the mouse spleens were 
removed through a flank incision. The spleens were macerated in 
phosphate buffered saline (PBS), pH 7.4. The lymphocytes were 
isolated by Histopaque gradient centrifugation and the cells were 
then washed in PBS (Boyum, 1968). The final lymphocyte pellet was 
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suspended in an appropriate concentration in PBS for fluorometric 
experiments, or in RPMI1640 (supplemented with 10% fetal bovine 
serum, 100 U/ml penicillin, and 100 ug/ml streptomycin (Gibco)) for 
short term lymphocyte cultures. Viability of the isolated 
lymphocytes, as determined by trypan blue exclusion was always 
greater than 90%. 
Short Term Lymphocyte Cultures. 0.10 ml of cells suspended in 
RPMI1640 in a concentration of 5 * 10 ̂  cells/ml were added to each 
of 96 wells of a microliter plate (Model 3040, Falcon Division, 
Becton-Dickinson, Oxnard, CA). In addition 0.05 ml of Con A in 
concentrations of 0 to 90 M-g/ml, and 0.02 ml of a beta-adrenergic 
antagonist solution were added to each well. Solutions of beta-
adrenergic antagonists were prepared by dissolving the appropriate 
compound in PBS, pH 7.4, PBS therefore served as a control when 
added to a microtiter plate well alone. Solutions added to the 
microtiter plate wells were first filtered through 0.22 micron 
filters (type GS, Millipore Corp., Bedford, MA). After a 24 h 
incubation period (at 37°C, with 5% CO2 and 95% air) each well was 
pulsed with 0.03 ml of tritiated thymidine (0.5 (iCi). Total well 
volume was 0.20 ml. Incorporated thymidine was harvested 24 h after 
pulsing on Whatman glass fiber filters with a cell harvestor (Model 
24V, Brandel, Gaithersburg, MD). Filters were air dried, placed in 
scintillation vials with 3 ml of LSC Complete (Yorktown Research, 
Miami, FL) and assayed for radioactivity to an accuracy of 0.05% in 
a Beckman Tri-Carb Scintillation Spectrophotometer (approximately 
58% tritium efficiency). 
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Beta-Adrenergic Antagonist Effects on the Normal Mitogen Dose-
Response. Microtiter plates were divided in half such that the top 
portion of the plate (4 rows x 12 columns) served as controls for 
the remaining wells of the plate. Wells in the top half of the 
plate each received mitogen, PBS, and cells. Remaining wells 
received in addition, an appropriate concentration of beta-
adrenergic antagonist in PBS. 
Steady-State Polarization Procedures. Cells were labeled with 
DPH following a procedure used by Kyoizumi et al. (1981). A 2 nM 
stock solution of DPH in tetrahydrof uran was used to prepare a 2 uM 
DPH solution in PBS. 2 ml of the 2 uM DPH solution was mixed with 2 
ml of a 2 * 10 cells per ml suspension and allowed to incubate at 
37°C for 45 min. After the incubation period, 3 ml of the DPH 
labeled cell mixture was placed in a quartz cuvette and polarization 
experiments conducted immediately. 
F-Con A bound cells were prepared in the following manner: 
Approximately 0.390 ml of the 8.0 mg/ml (protein) F-Con A stock was 
incubated with 5 * 10 ̂  cells/ml suspended in PBS at 37°C for 15 min. 
Following the incubation, the cell suspension was centrifuged at 150 
* g for 10 min and the pellet resuspended in PBS to a concentration 
of aout 1 * 10^ cells/ml. F-Con A bound cells were used immediately 
for polarization experiments. 
All drugs were first dissolved in PBS and then added to the 
cuvette in quantities of .3-40 Ml with Hamilton microliter 
syringes. Each drug addition was followed by a 15 minute incubation 
period before a polarization measurement was made. PBS added alone 
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in equal amounts and at similar times, as for drug addition, served 
as a control. 
Polarization was measured with an SLM 8000 spectrofluorometer 
interfaced with a Hewlett-Packard (HP) 85 computer for data 
analysis. Photomultiplier tubes were placed to the right and left 
of the sample cell with polarizers inserted in the emission and 
excitation beams. A Schott cut-on filter was placed in the 
horizontally polarized emission beam and an SLM MS320 monochromator 
placed in the perpendicularly polarized emission beam. Emission 
with the MC320 monochromator was monitored at 430 ran for DPH 
experiments and at 519 nm for F-Con A experiments. Fluorescence 
intensity was first measured with the sample excited (source, SLM 
Xenon arc lamp) with a parallel polarized beam, and then measured a 
second time with the sample excited with a perpendicularly polarized 
beam. For DPH experiments, the sample was excited with 360 nm 
light, and for the F-Con A experiments the sample was excited with 
492 nm light. The fluorometer was operated in the polarization mode 
P = A - B / A + B 
where P is the polarization, A is the fluorescence intensity 
parallel to and B the fluorescence intensity perpendicular to the 
plane of the polarizarized excitation beam. 
Background subtractions of cell-drug and fluorophore-drug 
contributions to polarizations measurements were made but were found 
not to be significant. This concentration of cells was not turbid 
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enough to cause significant light scattering. Temperature of the 
sample cell was controlled by a circulating water bath and the 
contents stirred with a magnetic stirrer. 
Membrane Potential Determination. A stock solution of diS-C3-
(5) was prepared by dissolving the dye in absolute ethanol. An 
aliquot of the stock solution was added to 3 ml of PBS or cells 
suspended in PBS in a quartz cuvette. The final concentration of 
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the dye was 10 M. The mixture was allowed to incubate at 37°C 
until the fluorescence emission was constant. Aliquots of potassium 
chloride were then added to the solution in the cuvette to obtain 
desired extracellular concentrations of potassium. Fluorescence 
emission was recorded following an addition of potassium. From the 
Goldman Field equation and the Nernst equation (assuming 
intracellular potassium concentration is .132 M (Deutsch et al., 
1979)), a change in membrane potential as a function of 
extracellular potassium was calculated (Deutsch et al., 1979). A 
membrane potential vs. % fluorescence curve was generated. In 
additional experiments valinomycin and propranolol were added to 
cuvettes conctaining diS-C3-(5) and cells in PBS to test for the 
possibility of dilutional or solute effects. 
The SLM instrument interfaced with a HP-85 as described above 
was used to determine the transmembrane potential of lymphocytes. 
The fluorometer was set-up for observing changes in fluorescence 
emission as a function of time in the single photon counting mode. 
The sample cell solution was excited with 622 nm light and 
fluorescent emission recorded at 670 nm. 
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From the changes in fluorescence emission recorded upon 
addition of potassium and valinomycin, a fluorescence-membrane 
potential calibration curve was generated. The limit of 
detectability, as calculated from the slope of the line multiplied 
by the mean counting error, was approximately 3% and corresponds to 
about 3 mV. 
Statistical Analysis. Data points (expressed as a % of 
Control) for the short term cultures in the figures represent the 
ratio of mean counts/min ̂ H-thymidine incorporated in the presence 
of the indicated concentration of beta-adrenergic antagonist 
(sample) divided by the mean counts/min ̂ H-thymidine incorporated in 
the absence of drug (control). This ratio is multiplied by 100. 
The mean response (counts/min %-thymidine incorporated) was 
calculated from quadruplicate samples or controls (standard 
deviations were less than 10%) in the presence of an optimal 
concentration of Con A (2.5 ug/ml). For polarization experiments, 
data points are the means of at least ten samples (standard 
deviations were less than 3%) and are expressed as the difference 
from the control. The statistical method of error propagation was 
applied as appropriate (Bevington, 1969). 
RESULTS 
Figures 1-4 show relationships between the short term cell 
culture results and the fluorescence polarization experiments with 
DPH and F-Con A. 
Propranolol, in Figure 1, suppresses the murine lymphocyte 
mitogen dose-response at concentrations of 10 (iM or greater. In 
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comparison, the effects of propranolol on the hydrophobic regions of 
the cell membrane appear to begin at a comparable concentration, as 
measured by the change in fluorescence polarization of DPH. In 
contrast, the effects of propranolol on cell surface dynamics as 
reported by the fluorescence polarization of F-Con A begin at a much 
higher concentration (approximately 500 u-M). Isomers of 
propranolol, Figure 2, produced similar results in the short term 
cultures and in the fluorescence polarization studies (DPH only) as 
were observed for the racemic propranolol. Alprenolol, in Figure 3, 
suppresses the mitogen dose-response at concentrations greater than 
10 p-M. Similar concentrations were required to alter the 
fluorescence polarization of DPH in the cell membrane. Alprenolol 
did not effect changes in the fluorescence polarization of F-Con A 
on the cell surface at any concentration tested. Metoprolol, Figure 
4, did not have a significant effect on the mitogen dose-response of 
lymphocytes in the short term culture system. There was little, if 
any, effect of metoprolol on the fluorescence polarization of DPH 
in the cell membrane and F-Con A on the cell surface. Sotalol, not 
shown, was not used in the cell culture system and fluorescence 
polarization experiments do not indicate the presence of significant 
sotalol effects (at any concentration) on the fluorescence 
polarization of either DPH in the cell membrane or F-Con A on the 
cell surface. 
The temperature-dependence of the fluorescence polarization of 
DPH in cell membranes and F-Con A on the surface of cell membranes 
was determined in the presence and absence of propranolol. Results 
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summarized in Figure 5 shew that 1000 |jM propranolol appears to 
affect the fluorescence polarization of DPH at different 
temperatures to differing degrees. At higher temperatures the 
polarization of DPH is altered to a larger degree than at lower 
temperatures. The appearance of a distinct transition temperature 
is not evident due to the heterogeneity of the membrane components 
of the lymphocyte. 1 u.M propranolol had little effect on the 
temperature-dependence of DPH in cell membranes. Concentrations of 
propranolol of 1000 \m produced a fairly parallel shift of the 
observed fluorescence polarization of F-Con A. Concentrations below 
100 UM have no effect. 
Figure 6 shows the calculated % membrane potential vs. % 
fluorescence change curve. The resting membrane potential of the 
lymphocyte was estimated to be approximately -65 mV. Elevation of 
extracellular potassium to about 200 irM results in an absolute 
decrease of the membrane potential to about -10 mV. Figure 7 is 
representative of the result of additions of propranolol up to 30 uM 
in concentration. In the concentration range tested (30 nM - 30 p.M) 
propranolol did not effect a change in the resting membrane 
potential. Following additions of propranolol, either valinomycin, 
a potassium ionophore, or potassium was added to the sample to test 
for the presence of a membrane potential. Valinomycin's presence 
results in decreased fluorescence emission (hyperpolarization) and 
addition of external potassium results in an increased fluorescence 
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Figure 1. Effect of dl-propranolol on the normal murine lymphocyte 
Con A dose-response and the fluorescence polarization of DPH and F-
Con A labeled murine lymphocytes. A) Con A dose-response in the 
presence of indicated concentrations of propranolol (+) expressed as 
a percent of the control (right ordinate). B) Fluorescence 
polarization of F-Con A in the presence of indicated concentrations 
of propranolol (•). C) Fluorescence polarization (left ordinate) of 
DPH in the presence of indicated concentrations of propranolol (o), 
Experiments were conducted as detailed in Materials and Methods. 
Ill 
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Figure 2. Effect of d- and 1- isomers of propranolol on the normal 
murine lymphocyte Con A dose-response and the fluorescence 
polarization of DPH labeled murine lymphocytes. A) Con A dose-
response in presence of indicated concentrations of d-propranolol 
(+) expressed as a percent of the control (right ordinate). B) Con 
A dose-response in the presence of indicated concentration of 1-
propranolol (o) expressed as a percent of the control (right 
ordinate). C) Fluorescence polarization of DPH in the presence of 
indicated concentrations of 1-propranolol (o). D) Fluorescence 
polarization of DPH in the presence of indicated concentrations of 
d-prqpranolol (+). Experiments were conducted as detailed in 
Materials and Methods. 
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Figure 3. Effect of alprenolol on the normal murine lymphocyte Con 
A dose-response and the fluorescence polarization of DPH and F-Con A 
labeled murine lymphocytes. A) Con A dose-response in the presence 
of indicated concentrations of alprenolol (+) expressed as a percent 
of the control (right ordinate). B) Fluorescence polarization of F-
Con A in the presence of indicated concentrations of alprenolol (•). 
C) Fluorescence polarization (left ordinate) of DPH in the presence 
of indicated concentrations of alprenolol (o). Experiments were 
conducted as detailed in Materials and Methods. 
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Figure 4. Effect of metoprolol on the normal murine lymphocyte Con 
A dose-response and the fluorescence polarization of DPH and F-Con A 
labeled murine lymphocytes. A) Con A dose-response in the presence 
of indicated concentrations of metoprolol (+) expressed as a percent 
of the control (right ordinate). B) Fluorescence polarization of F-
Con A in the presence of indicated concentrations of metoprolol (•). 
C) Fluorescence polarization (left ordinate) of DPH in the presence 
of indicated concentrations of metoprolol (o). Experiments were 
conducted as detailed in Materials and Methods. 
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Figure 5. Effect of propranolol on the temperature dependency of 
DPH and F-Con A. A) represents the fluorescence polarization of DPH 
and B), the effect of 1 nM propranolol on the fluorescence 
polarization of DPH, relative to changes in temperature. C) 
represents the effect of 1 mM propranolol on the fluorescence 
polarization of F-Con A and D), the fluorescence polarization of F-
Con A, relative to changes in temperature. At 20°C, C) (sample) is 
statistically different from D) (control), p < .005 (Student's t-
test), and at 25°, 30°, 35°, 40°, and 45°, C) (sample) is 
statistically different from D) (control), p < .001 (Student's t-
test). Experiments were conducted as detailed in Materials and 
Methods. 
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Figure 6. % changes of membrane potential relative to % fluorescence 
changes. See Materials and Methods for curve generation. 
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Figure 7. Fluorescence emission of DiS-C3-(5) labeled murine 
lymphocytes. A) is the fluorescence emission of diS-C3-(5) labeled 
murine lymphocytes indicating the resting membrane potential of the 
cell. B) effect of 30 uM propranolol on the fluorescence emission 
of diS-C3-(5) labeled cells. Experiments were conducted as detailed 
in Materials and Methods. 
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emission (depolarization). The resting membrane potential was not 
altered by addition of either sodium chloride or calcium chloride 
(not shown) before or after addition of propranolol. 
DISCUSSION 
Three fluorescent probes (DPH, F-Con A, and diS-C3-(5)) have 
been used in an attempt to characterize the nonspecific (non-
receptor mediated) effects of propranolol observed in short term 
cell cultures on the normal murine splenic lymphocyte mitogen dose-
response. Two other beta-adrenergic antagonists, sotalol and 
alprenolol, and a selective beta-l-adrenergic antagonist, 
metoprolol, were also included in experiments and the results used 
for comparison to results obtained for propranolol. 
Alterations of the fluorescence polarization of DPH have been 
interpreted as changes in the dynamic nature or "fluidity'1 of the 
hydrocarbon regions of live cells and artificial membranes (Johnston 
and Melnykovych, 1980; Kutchai et al., 1980; Pang et al., 1979; 
Fisher et al., 1979; Luly and Shinitzky, 1979; Johnson et al., 1979; 
Andrich and Vanderkooi, 1976; Shinitzky and Inbar, 1974; Shinitzky 
and Barenholz, 1974). For example, a decrease in the fluorescence 
polarization of DPH would be indicative of relative increases in the 
dynamic nature of the hydrocarbon regions around the probe. 
Results here show that propranolol concentrations in the ten 
micromolar range or greater produced a significant decrease in the 
fluorescence polarization of DPH in the cell membranes of 
lymphocytes. By extension, these observations would suggest that 
propranolol is increasing the dynamic nature of hydrophobic regions 
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of the lymphocyte cell membrane. Suppression of the normal mitogen 
dose-response in short-term cultures is observed over a similar 
concentration range of propranolol. In experiments with d- and 1-
propranolol isomers, similar results were observed. By comparison, 
alprenolol effected a decrease in the fluorescence polarization at 
slightly higher concentrations, greater than 10 jiM. In the short 
term cultures, alprenolol suppressed the normal mitogen dose-
response at concentrations greater than that observed for 
propranolol. Alprenolol, therefore, also appears to increase the 
relative dynamic nature of the hydrophobic regions of the lynphocyte 
membranes at drug concentrations similar to those observed as 
effective in suppression of the normal lymphocyte mitogen dose-
response. 
Metoprolol and sotalol did not alter the fluorescence 
polarization of DPH to a significant degree. Of these two 
compounds, only metoprolol was tested in the cell culture system and 
this compound did not alter the normal mitogen-dose response. On 
the basis of the fluorescence polarization of DPH, sotalol and 
metoprolol do not change to a significant degree the relative 
fluidity of the hydrophobic regions of the lymphocyte cell membrane. 
This observation might be predicted, since sotalol and metoprolol, 
compared to propranolol and alprenolol, have been shown to have 
relatively poor liposolubility characteristics (Dax and Partilla, 
1982; Woods and Robinson, 1981). Our results would suggest that 
very small changes in the hydrophobic regions around the probe have 
a significant affect on the responsiveness of the murine lymphocyte 
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to mitogenic stimulation. it has been suggested that the mobility 
of membrane components plays an important role in the immune 
response, possibly by modulation of specific ion permeabilities and 
uncoupling of transmembrane proteins (McConnell, 1978). 
Courtney (1980) indicated that various drugs could block 
frequency-dependent myocardial arrhythmias (Courtney, 1980). 
Concentrations of d- and 1- propranolol, and alprenolol necessary to 
produce frequency-dependent block were 5 uM and 20 \M, respectively 
(Courtney, 1980). Wbosley et al. (1977), have described similar 
propranolol concentrations as being required for control of 
ventricular arrhythmias. The above references to the use of 
propranolol or alprenolol for treatment of cardiac arrhythmia is of 
interest here based on the ability of propranolol and alprenolol to 
suppress the normal mitogen dose-response of lymphocytes over 
similar concentration ranges. In addition, relative changes in the 
hydrophobic regions of the lymphocyte membrane are noted at similar 
concentrations of propranolol and alprenolol. 
The concentrations of propranolol and alprenolol required for 
treatment of the cardiac arrhythmias noted above are much greater 
than for receptor mediated beta-adrenergic processes. These effects 
are found to be non-receptor mediated effects (non-specific effects) 
and are generally referred to as quinidine-like or local anesthetic 
effects. In theory, local anesthetics cause an increase in the 
relative dynamic nature of hydrophobic regions of cell membranes 
(Roth, 1979). Prom our results, it could be suggested that 
concentrations of propranolol and alprenolol that have local 
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anesthetic effects on the heart may also suppress the normal 
lymphocyte mitogen dose-response through a similar mechanism (local 
anesthetic effect or increased fluidity of the lymphocyte cell 
membrane). 
The fluorescence polarization of F-Con A has been used to study 
differences in cell surface dynamics and mobility of the Con A 
receptor on normal and malignant cells (Ben-Bassat et al., 1977; 
Inbar et al., 1973). In the lymphoid system, increases in the 
fluorescent polarization are interpreted as decreases in mobility of 
the Con A receptor and a decreased exposure of the Con A receptor to 
the aqueous environment. Decreased fluorescence polarization would 
be interpreted as the opposite, increased Con A receptor mobility 
and an increased exposure of Con A receptors to the aqueous 
environment (Ben-Bassat et al., 1977). Also increases in the 
dynamic nature of the hydrophobic regions of the lymphocyte membrane 
are consistent with a decreased mobility of the Con A receptors on 
the cell surface. The opposite conditions have also been suggested 
for cell surface Con A receptors and the hydrophobic regions of the 
cell membrane (Ben-Bassat et al., 1977). 
Of the four beta-adrenergic compounds that were tested, only 
propranolol altered the fluorescent polarization of F-Con A. 
Concentrations greater than 100 u-M propranolol were required to 
increase the polarization of F-Con A. This increase in the 
fluorescence polarization of F-Con A is consistent with a decrease 
in lymphocyte surface Con A receptor mobility. Since propranolol 
increases the dynamic nature of the hydrophobic regions of the 
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lymphocyte membrane at these concentrations, the decreased mobility 
of the cell surface Con A receptor observation is consistent with 
the idea of increased fluidity of hydrocarbon regions paralleling 
decreased cell surface dynamics (Ben-Bassat et al., 1977). However, 
there is a significant difference between the concentrations at 
which there is an alteration of cell surface component dynamics and 
the alteration of the hydrophobic regions of the cell membrane. 
This difference in concentration dependency suggests that 
alterations of the hydrophobic regions of the cell membrane must be 
significantly large before cell surface Con A receptors are affected 
to a significant degree. 
The temperature-dependent fluorescence polarization of DPH, and 
of F-Con A was completed both in the presence and absence of 
propranolol. At higher temperatures there is a greater fluidity of 
the lymphocyte membrane in the presence of propranolol than at lower 
temperatures where the effect of propranolol diminishes. The effect 
of propranolol on the DPH curve may be indicative of selectivity of 
propranolol for certain hydrophobic regions of the lipid matrix of 
the cell membrane or hydrophobic regions of some proteins. In 
contrast, propranolol causes an upward shift of the fluorescence 
polarization of F-Con A. Therefore, the presence of propranolol 
decreases the mobility of the Con A receptor uniformly at all 
temperatures. Given that the relative fluidity of the cell membrane 
is increased, the decrease in mobility of the F-Con A receptors is 
consistent. 
The membrane potential of the murine splenic lymphocyte has 
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been determined to be approximately -65 mV. This is in agreement 
with the -65 mV determined by Kiefer et al. (1980) (using ^H-
tetraphenylphosphonium). DiS-C3-(5) provides a useful monitor of 
the resting membrane potential and reflects changes of the membrane 
potential (hyperpolarization or depolarization) that may occur as a 
result of a stimulus (Waggoner, 1979). With diS-C3-(5) the 
lymphocyte resting membrane potential was monitored for alterations 
induced by various concentrations of propranolol. A significant 
change could not be distinguished at any concentration of 
propranolol tested. Therefore propranolol does not appear to 
influence the resting membrane potential. It is important to note 
that concentrations of propranolol which resulted in a significant 
change in the fluidity of the hydrophobic regions of the cell 
membrane (30 p.M) did not appear to alter membrane permeability to 
potassium. Addition of external potassium to cell suspensions 
resulted in depolarization regardless if added before or after 
propranolol. It is difficult to determine whether or not sodium or 
calcium permeability is altered relative to the lymphocyte membrane 
since neither alters the membrane potential when external levels are 
elevated in the absence of propranolol. 
In recent years it has become popular to describe the actions 
of a xenobiotic as occurring through receptor mediated processes. 
From data presented here, and in other recent studies (Dax and 
Partilla, 1982; Woods and Robinson, 1981; Deacon et al., 1981), it 
is apparent that the non-receptor mediated activity of a xenobiotic 
such as propranolol may be of substantial significance, along with 
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the traditional beta-receptor mediated processes. Therefore, it 
remains important to characterize non-receptor mediated mechanisms 
that may or may not produce significant alterations in biological 
systems. 
In summary, the data suggests that concentrations of 
propranolol and alprenolol (non-selective beta-adrenergic 
antagonists) that suppress that normal lymphocyte Con A dose-
response are similar to the concentrations of propranolol and 
alprenolol that increase the relative fluidity of the hydrophobic 
regions of the lymphocyte cell membrane. Also, metoprolol, a beta-
1-adrenergic antagonist, does not alter either the normal lymphocyte 
mitogen dose-response or the relative dynamic nature of the 
hydrophobic regions of the cell membrane. Sotalol, another non-
selective beta-adrenergic antagonist, does not alter the relative 
fluidity of the cell membrane. Propranolol alone was also shown to 
alter the mobility of the Con A receptor on the lymphocyte cell 
surfaces but at concentrations significantly higher than those 
altering the fluidity of the hydrophobic regions of the lymphocyte 
cell membrane. In temperature-dependent polarization experiments 
with DPH, propranolol may affect different hydrophobic regions of 
the lymphocyte cell membrane to differing degrees. At low 
temperatures propranolol had little effect on the fluidity of the 
lymphocyte cell membrane but, at high temperatures, propranolol 
significantly increased the relative dynamic nature of the 
lymphocyte cell membrane. In temperature-dependent polarization 
experiments with F-Con A, propranolol effected a parallel decrease 
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in cell surface Con A receptor mobility at all temperatures. 
Propranolol does not alter the resting membrane potential of the 
murine lymphocyte or the lymphocyte's permeability to potassium. 
A(ZKN0WIJEIX5EME]S1TS 
Cell culture results, membrane potential calculations, and 
membrane potential calibration curves represent the contribution of 
Dr. Douglas L. Johnson, University of South Dakota School of 
Medicine, Vermillion, South Dakota, to this work. 
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EXPERIMENTAL STUDIES 
PART IV 
EFFECT OF TRICYCLIC ANTIDEPRESSANT DRUGS ON LYMPHOCYTE 
MEMBRANE STRUCTURE 
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ABSTRACT 
Tricyclic antidepressant-induced perturbations of murine 
splenic lymphocyte membranes and cell surface concanavalin A 
receptor mobility have been investigated using the fluorescent 
probes diphenyIhexatriene and f luorescein-conjugated concanavalin A. 
Results of these studies illustrate the possible relationship 
between tricyclic antidepressant-induced membrane perturbations and 
tricyclic antidepressant-induced suppression of the normal murine 
lymphocyte mitogen response. Tricyclic antidepressant effects on 
murine splenic lymphocyte membranes are dose-, time- and 
temperature- dependent. Murine lymphocyte concanavalin A cell 
surface receptor mobility is not apparently altered by the tricyclic 
antidepressants. 
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INTRODUCTION 
The therapeutic application of tricyclic antidepressant drugs 
in the management of affective disorders is well known. The precise 
mechanism of action for these drugs, however, remains unresolved 
(Sulser, 1982). Specific binding sites for tricyclic 
antidepressants have been identified on membrane preparations of 
brain (Dumbrille et al., 1981; Kinnier et al., 1981; Rehavi et al., 
1981; and Raisman et al., 1979), platelets (Langer et al., 1981; and 
Wennogle et al., 1981), lymphocytes (Audus and Gordon, 1982a), and 
lung (Raisman and Langer, 1983). Since the role of these binding 
sites in tricyclic antidepressant therapy is not clearly established 
(Sulser, 1982), it is of interest to investigate other tricyclic 
antidepressant drug-membrane interactions that may contribute to an 
understanding of the pharmacology of the tricyclic antidepressants. 
It has been demonstrated that the tricyclic antidepressants 
suppress the normal mitogenic response (Audus and Gordon, 1982b; 
Nahas et al., 1979, Smith et al., 1978; and Waterfield et al., 1976) 
and the number of plaque forming cells (Smith et al., 1978) in short 
term cultures of murine splenic lymphocytes. The concentrations (10 
(iM or greater) of the tricyclic antidepressants that suppress the 
normal mitogenic response and the number of plaque forming cells in 
culture, are much greater than the apparent K d (.4 nM) for the 
tricyclic antidepressant binding site (Audus and Gordon, 1982b). 
Therefore, it is probable that the suppression of the mitogenic 
response and the reduction in the numbers of plaque-forming cells in 
the short term cultures of murine splenic lymphocytes is not 
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mediated by the specific high affinity binding site. Moreover, 
concentrations at which the tricyclic antidepressants depress murine 
lymphocyte responses in the short term cultures described above, are 
similar to those concentrations of tricyclic antidepressants which 
are known to alter the phase-transition of lipids in artificial cell 
membranes (Romer and Bickel, 1979; Bermejo et al., 1975; Cater et 
al., 1974; and Bermejo et al., 1974). 
In this report, we present data that illustrates the 
relationship between the concentrations of tricyclic antidepressants 
that alter the lipid or hydrophobic domains of murine splenic 
lymphocyte membranes, as monitored by a fluorescent probe, and the 
concentrations of tricyclic antidepressants that alter murine 
splenic lymphocyte mitogenesis, a cellular process in which the cell 
membrane lipids play a significant role (Gurr, 1983). In addition, 
tricyclic antidepressant effects on the mobility of the Concanavalin 
A receptor, as monitored by a fluorescent probe, and the time and 
temperature dependency of the tricyclic antidepressant effects on 
lymphocyte membranes, will be described. 
The fluorescent probes used in this study are 1,6-diphenyl-
1,3,5-hexatriene (DPH), and fluorescein conjugated Concanavalin A 
(F-Con A). DPH, a highly lipophilic fluorescent probe, has been 
used to characterize structural perturbations in the lipid or 
hydrophobic domains of live and artificial cell membranes in 
response to temperature (Andrich and vanderkooi, 1976) and pressure 
changes (Lackowicz and Thompson, 1983), disease (Ben-Bassat et al., 
1977: Inbar, 1976; Shinitzky and Inbar, 1974; and Inbar et al., 
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1973), and various pharmacologically active compounds (Audus et 
al., 1983; Kutchai et al., 1980; Johnston and Melnykovych, 1980; and 
Luly and Shinitzky, 1979). F-Con A has been used to study 
alterations of cell surface Concanavalin A receptor mobility in the 
presence of disease and pharmacologically active compounds (Audus et 
al., 1983; Ben-Bassat et al., 1977; Shinitzky and Inbar, 1974; and 
Inbar et al., 1973). 
MATERIALS AND METHODS 
l,6-Diphenyl-l,3,5-hexatriene (lot no. 2021A) was purchased 
from Molecular Probes, Inc., Junction City, OR. Fluorescein 
conjugated Concanavalin A (lot no. 00387; fluorescein/protein 
(molar): 4.9) and Concanavalin A (lot no. 910026) were purchased 
from Calbiochem-Behring Corp., La Jolla, CA. Desipramine HC1 was a 
gift from Merrell Dow Pharmaceutical Inc., Cincinnati, OH. 
Nortriptyline HC1 was a gift from Lilly Research Laboratories, 
Indianapolis, IN. Protriptyline HC1 was a gift from Merck, Sharp & 
Dohme Research Laboratories, West Point, PA. Phosopholipids and 
imipramine HC1 (lot no. 121F-0086) was purchased from Sigma Chemical 
Co., St. Louis, MO. Thymidine, (6-%)-, was purchased from New 
England Nuclear, Boston, MA. All other compounds used were of the 
highest grade commercially available. 
Lymphocyte Isolation. Outbred, adult male mice (25-30 g) were 
sacrificed by cervical dislocation and spleens removed. The spleens 
were macerated in phosphate buffered saline (PBS), pH 7.4, 
lymphocytes isolated by Histopaque gradient centrifugation and 
washed in PBS (Boyum, 1968). The final lymphocyte pellet was 
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suspended in an appropriate concentration in PBS for fluorometric 
experiments, or in RPMI 1640 (supplemented with 10% bovine serum, 
100 U penicillin, and 100 fig streptomycin) for short-term lymphocyte 
cultures. Viability of the isolated lymphocytes, as determined by 
trypan blue exclusion was always greater than 90%. 
Short Term Lymphocyte Cultures. Methodology for conducting the 
short-term cultures used in this study have been described in detail 
in previous work (Audus and Gordon, 1982b). Briefly, 0.01 ml 
aliguots of lymphocytes suspended in RPMI 1640 were added to 
microtiter plates (Model 3040, Falcon Division, Becton-Dickinson, 
Oxnard, CA). 0.05 ml of Con A in concentrations of 0 to 90 M-g/ml, 
and 0.02 ml of an appropriate concentration of tricyclic 
antidepressant or PBS were also added to each of the 96 wells. The 
cultures were incubated at 37 °C, with 5% CO2 and 95% air. Each 
well was pulsed with 0.03 ml tritiated thymidine (0.5 \xCi), bringing 
the total well volume to 0.2 ml. Incorporated labeled thymidine was 
collected on Whatman glass fiber filters with a cell harvester 
(Model 24V, Brandel, Gaithersberg, MD). Filters were air dryed, 
then placed in scintillation vials with 3 ml of LSC Complete 
(Yorktown Research, Miami, FL) and radioactivity assayed to an 
accuracy of 0.5% in a Beckman Tri-Carb Scintillation Spectometer 
(approximately 58% tritium efficiency). 
Tricyclic Antidepressant Effects on the Normal Mitogen Dose-
Response. Microtiter plates were divided in half such that the top 
half of the plate (4 rows x 12 columns) served as controls for the 
raining wells of the plate. Control wells received aliguots of 
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PBS not containing a tricyclic antidepressant in addition to mitogen 
and cells. Remaining wells received in addition, an appropriate 
concentration of a tricyclic antidepressant. 
Cell Labeling Procedure. Cells were labeled with DPH as 
described previously (Audus et al., 1983). 2 * 10 6 cells/ml in PBS 
were mixed (1:1; v/v) with a 2 \m solution of DPH in PBS, incubated 
at 37 0 C for 45 min, and washed with PBS. 3 ml of DPH labeled cell 
solution was placed in a quartz cuvette and fluorescence anisotropy 
and lifetimes measured immediately. The final concentration of DPH 
was 1 MM and the final concentration of cells was approximately 1 * 
10 6 cells/ml. 
The procedure for labeling cells with F-Con A has been 
described in a prior report (Audus et al., 1983). Approximately 
.390 ml of 8.0 mg/ml (protein) F-Con A stock was incubated with 5 * 
f> o 10 cells/ml suspended in PBS at 37 C for 15 min. Following 
incubation, the cell suspension was centrifuged at 150 * g for 15 
min and the pellet resuspended in PBS to a final concentration of 
about 1 * 10^ cells/ml. F-Con A labeled cells were used 
immediately in fluorometric measurements. 
All drugs were dissolved in distilled water or PBS and added to 
the fluorometer cuvettes in aliquots of 1-40 Ml with a Hamilton 
microliter syringe. Each drug addition to the cuvette was followed 
by a 5 min (unless otherwise stated) incubation period before a 
fluorescence polarization or lifetime measurement was made. 
Aliquots of PBS or distilled water containing no drug, added in 
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equal amounts and at similar times, as for drug addition, served as 
a control. 
Fluorescence Anisotropy Measurements. Fluorescence anisotropy 
measurements were made with an SLM 8000 interfaced with an Hewlett-
Packard 87 computer for on-line data acquisition and analysis as 
described previously (Audus et al., 1983). Photomultiplier tubes 
were placed to the right and left of the sample cell with polarizers 
inserted in the emission and excitation beams. A Schott KV-389 cut 
on filter was placed in the horizontally polarized emission beam and 
an SLM MC320 monochromator placed in the vertically polarized 
emission beam. Emission was monitored at 430 nm for DPH experiments 
and at 519 nm for F-Con A experiments. Fluorescence intensity was 
first measured with the sample excited (source, 450 W Xenon arc 
lamp) with a horizontally polarized beam, and then measured a second 
time with the sample excited with a vertically polarized beam. For 
DPH experiments the sample was excited with 360 nm light, and for 
the F-Con A experiments the sample was excited with 492 nm light. 
The fluorometer was set up to measure fluorescence anisotropy 
r = A - B / A + 2B 
where r is anisotropy. A is the ratio of the fluorescence 
intensities parallel and perpendicular to the plane of polarized 
excitation light with the excitation polarizer in the vertical 
position. B is the ratio of the fluorescence intensities parallel 
and perpendicular to the plane of polarized excitation light with 
the excitation polarizer in the horizontal position. 
Background subtractions of cell + drug and fluorophore + drug 
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contributions were made but were not found to be significant 
(exception tricyclic antidepressant-F-con A interactions see Results 
and Discussion sections). Light scattering due to turbidity of the 
cell suspension was also insignificant. The tricyclic 
antidepressants absorb in the uv region (maximally around 250 nm) 
well below the excitation wavelength for DPH (360 nm) and did not 
significantly contribute to the fluorescence of the labeled 
lymphocytes. The temperature of the sample cell was controlled by a 
circulating water bath and the contents of the sample cuvette 
stirred with a magnetic stirrer. 
Fluorescence Lifetime Measurements. Fluorescence lifetimes 
were calculated from phase and modulation measurements made with an 
SLM 4800 subnanosecond fluorometer interfaced with a Hewlwett 
Packard 87 computer for on-line acquisition and analysis. 
Excitation light was passed through a MC320 monochromator set at the 
excitation wavelength of DPH (360 nm with a bandpass of .5 nm) and 
the intensity was modulated at 30 MHz by a Debye-Sears light 
modulator. Emission wavelengths were selected by Schott cut-on 
filters, RG630 for the reference channel, and a KV389 filter for the 
sample chamber. A rhodamine quantum counter solution in a 
triangular cell was placed in the reference chamber. In the sample 
chamber, a sample solution (DPH labeled cells) and a reference 
solution (dimethyl POPOP, a fluorophore with a known lifetime of 
1.45 nsec dissolved in ethanol) was placed in the two sample turret. 
Fluorescence emission from the two solutions was balanced by 
diluting the dimethyl POPOP solution. 
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The contents of the cuvettes in the sample chamber were stirred 
continuously with a magnetic stirrer and the temperature of the 
sample chamber controlled by a circulating water bath. A polarizer 
set at approximately 55° to the vertical was placed in the emission 
beam to eliminate Brownian rotation effects (Spencer and Weber, 
1970). 
The phase shift and the modulation of each sample was measured 
alternately 4 times, with the time interval between each measurement 
of about 10 sec. Data was acquired by the interfaced computer, 
averaged and the lifetimes calculated from the following basic 
relationships: 
Tphase = 1/w tan 9 
T mod.= (Vw) [l/D2-!)1/2 
where Tphase * s the phase lifetime, 9 the phase shift in degrees 
caused by a sample of lifetime T, w is the angular frequency of 
excitation which is 2 * pi * modulation frequency (30 MHz), T m o d > 
is the modulation lifetime, and D is the ratio 
Mfiuorophore/M reference, w h f ire M represents the relative 
modulation of a reference solution. 
The basic theory of fluorescence lifetime calculations from 
phase-modulation measurements follows from the fact that emission 
from fluorescent species, excited by sinusoidally modulated light, 
will be phase shifted and demodulated relative to the exciting light 
by an amount dependent on the fluorophore lifetime. 
(Characteristically, the modulation lifetime will always be greater 
than the phase lifetime in a system with a heterogenous distribution 
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of emitting fluorophores.) Detailed methodology and discussion of 
the theory of fluorescence lifetime calculations from phase-
modulation measurements is described elsewhere (Lackowicz, 1983). 
RESULTS 
Figure 1 illustrates the dose-dependent effects of 
protriptyline and nortriptyline on the fluorescence anisotropy of 
DPH in murine splenic lymphocytes, with increasing concentrations 
of protriptyline and nortriptyline, there is a corresponding 
decrease in the fluorescence anisotropy of DPH. Additions of equal 
aliquots of PBS at similar times, as for nortriptyline and 
protriptyline additions, did not alter the fluorescence anisotropy 
of DPH. Reproducible tricyclic antidepressant effects on the 
fluorescence anisotropy of DPH begin at a concentration of about 30 
uM. Protriptyline and nortriptyline do not quench DPH fluorescence 
to a significant degree at concentrations less than 1 nM (results 
not shown). 
Figure 2 shows the dose-dependent decrease in the fluorescence 
lifetime of DPH in the presence of increasing concentrations of 
either desipramine or imipramine. Reproducible quenching of DPH 
fluorescence by desipramine and imipramine begins at a concentration 
of approximately 10 uM for desipramine and 30 u-M for imipramine. 
Additions of equal aliquots of water at similar times, as for 
desipramine and imipramine additions, did not alter the fluorescence 
lifetime of DPH. Desipramine produces a dose-dependent increase in 
the fluorescence anisotropy of DPH that parallels effects on the 
fluorescence lifetime of DPH (not shown). In contrast, the 
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fluorescence anisotropy of DPH in murine lymphocyte membranes does 
not consistently increase or decrease in the presence of increasing 
concentrations of imipramine. 
Data in Figure 3 illustrates tricyclic antidepressant effects 
on the murine lymphocyte mitogen response. Note that at a 
concentration of 1 UM, for each of the four tricyclic 
antidepressants, little supression of the mitogen response is 
observed while at a concentration of 10 uM, for each of the four 
tricyclic antidepressants, the mitogen response is suppressed to 50-
60% of the control. At a concentration of 100 jiM, for each of the 
four tricyclic antidepressants, almost complete suppression of the 
mitogen is observed. 
In figures 4 and 5, DPH fluorescence anisotropy or fluorescence 
lifetime is plotted versus time (min) in the presence of the 
indicated concentration of tricyclic antidepressant. All of the 
tricyclic antidepressants produced maximal effects on either 
fluorescence anisotropy or fluorescence lifetime within five minutes 
after injection into a suspension of DPH labeled lymphocytes. 
DPH fluorescence anisotropy or fluorescence lifetime is plotted 
versus temperature in figures 6 and 7. Nortriptyline and 
protriptyline at a concentration of 100 uM produce a decrease in the 
fluorescence anisotropy that is reversible with decreasing 
temperatures. Desipramine and imipramine at a concentration of 100 
M produce a decrease in the fluorescence lifetime of DPH that is 
also reversible with decreasing temperatures. 
The fluorescence anisotropy of F-Con A is not altered in the 
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Figure 1. Effect of Nortriptyline and Protriptyline on the DPH 
Fluorescence Anisotropy in Murine Splenic Lymphocytes. A) Initial 
value of DPH fluorescence anisotropy was .1842 +/- .002 for the 
sample receiving indicated concentrations of nortriptyline (o). B) 
Initial value of DPH fluorescence anisotropy was .1753 +/~ .003 for 
the sample receiving indicated concentrations of protriptyline (+). 
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Figure 2. Effect of Desipramine and imipramine on the DPH 
Fluorescence Phase Lifetime in Murine Splenic Lymphocytes. A) 
Initial value of the DPH fluorescence phase lifetime was 7.961 +/-
,048 for the sample receiving indicated concentrations of 
desipramine (o), B) Initial value of the DPH fluorescence phase 
lifetime was 8.166 +/~ .096 for the sample receiving indicated 
concentrations of imipramine (+). 
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Figure 3. Effect of the Tricyclic Antidepressants on the Normal 
Mitogenic Response of the Murine Splenic Lymphocyte. Each data 
point, expressed as a percent of a control, represents the mean 
counts of tritiated thymidine incorporated in the presence of the 
indicated concentrations of tricyclic antidepressant divided by the 
mean counts of tritiated thymidine incorporated without a tricyclic 
antidepressant present (control) times 100%. The mean counts of 
tritiated thymidine were calculated from quadruplicate samples in 
the presence of an optimal concentration of concanavalin A (10 
|ig/ml). (nortriptyline (o); protriptyline (+); desipramine (•); 
imipramine (•). 
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Figure 4. Time Course of Nortriptyline and Protriptyline Effects on 
the DPH Fluorescence Anisotropy in Murine Splenic Lymphocytes. A) 
300 (j.M nortriptyline (o) was added to DPH labeled murine lymphocytes 
and the fluorescence anisotropy recorded at one minute intervals. 
B) 100 |iM protriptyline (+) was added to DPH labeled murine 
lymphocytes and the fluorescence anisotropy recorded at one minute 
intervals. 
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Figure 5. Time Course of Desipramine and Imipramine Effects on the 
DPH Fluorescence Phase Lifetime in Murine Splenic Lymphocytes. A) 
100 (iM desipramine (o) was added to DPH labeled murine lymphocytes 
and the fluorescence phase lifetime recorded at one minute 
intervals. B) 100 |iM imipramine was added to DPH labeled murine 
lymphocytes and the fluorescence phase lifetime recorded at one 
minute intervals. 
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Figure 6. Temperature Dependency of the Effects of Nortriptyline 
and Protriptyline on the DPH Fluorescence Anisotropy in Murine 
Splenic Lymphocytes. A) 100 uM nortriptyline (+), B) 100 |iM 
protriptyline (o), and C) an equal amount of PBS (control, x), was 
added to DPH labeled lymphocytes and the fluorescence anisotropy 
recorded at five degree intervals. 
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Figure 7. Temperature Dependency of the Effects of Desipramine and 
Imipramine on the DPH Fluorescence Phase Lifetime in Murine Splenic 
Lymphocytes. A) 100 \M desipramine (+), B) 100 (iM imipramine (o), 
and C) an equal amount of PBS (control, x), was added to DPH labeled 
lymphocytes and the fluorescence phase lifetime recorded at 5 degree 
intervals. 
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presence of any of the four tricyclic antidepressants (results not 
shown). Although changes in the fluorescence anisotropy of F-Con A 
can be observed at concentrations of about 1 nM, these effects 
appear to be due to a direct interaction of the tricyclic 
antidepressants with the F-Con A since results in the presence and 
absence of cells are similar. 
DISCUSSION 
This study was conducted to compare directly tricyclic 
antidepressant induced effects on the lipid or hydrophobic domains 
of lymphocyte membranes and lymphocyte cell surface Con A receptors, 
with the tricyclic antidepressant induced effects on lymphocyte 
mitogenesis in short term cultures. 
DPH fluorescence anisotropy has been used in a number of 
studies to characterize changes in membrane "fluidity" or to 
estimate the viscosity of live (Kutchai et al., 1980; Johnston et 
al., 1980; Luly and Shinitzky, 1979; and Inbar 1976) and artificial 
(Iackowicz and Thompson, 1983; Johnson et al., 1979; Pang et al. 
1979; and Andrich and Vanderkooi, 1976) cell membranes. However, in 
a biomembrane, DPH experiences hindered rotations due to structural 
constraints in the hydrophobic microenvironment of the DPH molecule 
and therefore, the fluorescence anisotropy of DPH in biomembranes 
is representative of the degree of structural order in the 
hydrophobic or lipid microenvironment of the DPH molecule (Lackowicz 
et al., 1979; Lackowicz and Prendergast, 1978a; and Lackowicz and 
Prendergast, 1978b). For example, the fluorescence anisotropy of 
DPH in a biomembrane decreases with increasing temperatures (Andrich 
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and Vanderkooi, 1976). The decrease fluorescence anisotropy may be 
appropriately interpreted as a decrease in the structural order of 
the lipid microenvironment of the DPH molecule. in contrast, an 
increase in the fluorescence anisotropy of DPH in a biomembrane, 
observed in the presence of decreasing temperatures (Andrich and 
Vanderkooi) or increased hydrostatic pressure (Lackowicz and 
Thompson, 1983), could be interpreted as an increased ordering of 
the lipid microenvironment of the DPH molecule. An increased 
fluorescence anisotropy can also result from the quenching of DPH 
fluorescence emission. Therefore, the fluorescence lifetime, which 
decreases as a result of some types of quenching, is used to 
properly interpret fluorescence anisotropy measurements (Lackowicz, 
1983). 
Desipramine, imipramine, nortriptyline, and protriptyline can 
be placed into two groups based on their effects on the fluorescence 
anisotropy and lifetime of DPH, Nortriptyline and protriptyline 
produce a dose-dependent decrease in DPH fluorescence anisotropy and 
have no significant effect on the fluorescence lifetime of DPH 
except at very high concentrations (nM). These results are 
interpreted as drug-induced perturbations of the structural order of 
the lipid microenvironment of the DPH molecule in the murine 
lymphocyte membranes. Etesipramine, on the other hand, produces an 
increase in DPH fluorescence anisotropy and a corresponding decrease 
in the fluorescence lifetime of DPH in murine lymphocyte membranes. 
Imipramine, like desipramine, produces a dose-dependent decrease in 
the fluorescence lifetime of DPH and produces neither a consistent 
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increase nor decrease in the fluorescence anisotropy of DPH. The 
drug-induced effects of desipramine and imipramine on the 
fluorescence of DPH are interpreted as quenching effects. The 
results of the fluorescence experiments, involving desipramine and 
imipramine, indicate that the respective drugs can diffuse into 
murine lymphocyte membranes and directly interact with the DPH 
molecule during the excited state resulting in a quenching of the 
fluorescence emission of DPH. The drug-induced quenching of DPH 
fluorescence by imipramine and desipramine is probably collisional, 
since, spectral overlaps between DPH, and desipramine and imipramine 
are not observed. 
The concentrations at which desipramine and imipramine quench 
DPH fluorescence are similar to those concentrations of 
nortriptyline and protriptyline that induce perturbations of the 
structural order of the lipid domains of the murine lymphocyte. 
Other indirect and direct techniques, ESR and NMR, however, show 
that concentrations of desipramine and imipramine that produce 
structural perturbations in model membranes are similar to those 
concentrations of desipramine and impramine that quench DPH 
fluorescence (Romer and Bickel, 1979; Bermejo et al., 1975; and 
Bermejo et al., 1974). Therefore, the evidence suggests that 
nortriptyline and protriptyline, and most likely, desipramine and 
imipramine, produce structural perturbations in murine splenic 
lymphocyte membranes that are probably consistent with membrane 
perturbations produced by local anesthetics. 
The partition coefficients of the tricyclic antidepressants 
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used in this study are similar (Frisk-Holmberg and van der Kleijn, 
1972). It is not surprising then, that the concentrations (>1 |iM) 
of tricyclic antidepressant necessary to alter DPH fluorescence 
anisotropy or lifetime in the lipid domains of the murine 
lymphocyte, are similar for one tricyclic antidepressant as compared 
to another. 
In the short term cultures, the tricyclic antidepressants, at 
concentrations that induce membrane structural perturbations, as 
monitored by DPH, inhibited mitogenesis. Nortriptyline, for 
example, began to perturb the murine lymphocyte membrane at a final 
concentration of about 30 (iM, and depress mitogenesis at a final 
concentration of 10 [iM. By comparison, desipramine began to quench 
DPH fluorescence at a concentration of about 10 jiM, and depress 
mitogenesis at a final concentration of 10 iiM. Studies with 
protriptyline produced experimental results similar to those 
described for nortriptyline and for imipramine, experimental results 
were similar to those for desipramine. These results suggest that 
there may be a relationship between tricyclic antidepressant induced 
membrane perturbations in the murine lymphocyte, and the inhibition 
of murine lymphocyte mitogenesis. 
The peak therapeutic plasma concentrations of tricyclic 
antidepressants approach, for example, 2.5 ̂ M for imipramine (Perel 
et al., 1976). However, tricyclic antidepressants can accumulate in 
cells and tissues in greater concentrations than observed in the 
plasma. Concentrations of tricyclic antidepressants in brain 
tissue, for instance, in the presence of therapeutic plasma levels, 
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axe 1 to 10 uM. The ratio of the brain tissue concentration of 
tricyclic antidepressants to plasma concentration concentration of 
tricyclic antidepressants, is a function of plasma concentration, 
ranging from 40:1 to 8:1 with increasing plasma concentration 
(Glotzbach and Preskorn, 1982). Tricyclic antidepressants can also 
accumulate in erythrocytes. The concentration of tricyclic 
antidepressants in the erythrocyte is up to 6-fold higher than the 
plasma concentration in patients treated for depression. it has 
been suggested that the ratio of tricyclic antidepressant 
concentration in the erythrocyte to the plasma tricyclic 
antidepressant concentration is similar to the ratio of tricyclic 
antidepressant concentration in brain tissue to the plasma tricyclic 
antidepressant concentration (Matuzas et al., 1983; and Linnoila et 
al., 1978). We are not aware of any reports demonstrating tricyclic 
antidepressant accumulation in the lyn^ocyte, although, lymphocytes 
have been reported to uptake other liposoluble compounds such as 
antiarrhythmic agents (Somani et al., 1983). 
It is probable that after long chronic treatment, tricyclic 
antidepressants may accumulate in sufficiently high enough 
concentrations in the lymphocyte in vivo to induce membrane 
structural perturbations that may result in altered lymphocyte 
function or lymphocyte numbers. At least one report describes the 
effectiveness of imipramine in reducing elevated rheumatoid antibody 
titers in patients with or without depression (Haydu et al., 1974). 
Moreover, alterations of lymphocyte populations in patients have 
been described following long-term therapy with imipramine (Leyberg 
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and Denmark, 1959), and other highly liposoluble agents such as 
phenothiazines (Enake et al., 1978). This study, then, provides 
information about tricyclic antidepressant-cell membrane 
interactions that may be representative of drug effects occuring 
after long-term therapy with tricyclic antidepressants. 
Tricyclic antidepressant effects on the murine lymphocyte are 
time-dependent. All of the tricyclic antidepressants used in this 
study produce maximal membrane perturbations, as represented by 
alterations of DPH fluorescence anisotropy or lifetime, within 5 min 
at 37° C. It is apparent from the time course studies of the 
tricyclic antidepressants in the short term cultures (Audus and 
Gordon, 1982b), that these compounds produce the greatest inhibition 
of the mitogenic response if present in the cultures during the 
first 24 h of the culture. This initial 24 h period of the culture 
period represents a time frame during which cellular events take 
place that determine whether the lymphocyte will undergo 
mitogenesis. These results suggest that the tricyclic 
antidepressants apparently reach a rapid equilibrium distribution in 
the lymphocyte and that these drugs are most effective in inhibting 
the mitogenic response during the time period in which the cell 
experiences the dynamic membrane and cytoplasmic events that lead to 
mitogenesis. 
The tricyclic antidepressant-induced membrane perturbations can 
be reversed in the presence of decreasing temperatures. The 
membrane perturbations produced by protriptyline and nortriptyline, 
as monitored by DPH fluorescence anisotropy, indicate that 
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nortriptyline and protriptyline may preferentially dissolve in 
different lipid phases or that the increasing structural order of 
the membrane lipids, with decreasing temperatures, may force these 
drugs out of the membrane. Experimental results with nortriptyline 
and protriptyline are consistent with observations of the 
temperature-dependency of other drug-induced membrane perturbations 
in the murine lymphocyte (Audus et al., 1983). 
Desipramine and imipramine quenching of the DPH fluorescence 
lifetime was also reversed in the presence of decreasing 
temperatures. These results indicate that the quenching of DPH 
fluorescence is diffusion dependent and that the quenching is 
probably due to collisions (dynamic quenching) between DPH, and 
desipramine and imipramine. If the quenching of the DPH 
fluorescence was due to the formation of drug-fluorophore complexes 
(static quenching) one would not have observed a reversal of the 
quenching with decreasing temperature (Lackowicz, 1983). The 
reversal of tricyclic antidepressant induced membrane perturbations 
with decreasing temperatures is a characteristic shared by local 
anesthetics or anesthetics (Roth, 1979). 
Alterations of the fluorescence anisotropy of F-Con A have 
been interpreted as changes in cells surface dynamics and changes in 
the mobility of the Con A receptor (Ben-Bassat et al., 1977; 
Shinitzky and Inbar, 1974; and Inbar et al., 1973). Increased 
fluorescence polarization is interpreted as decreases in the 
mobility of the Con A receptor and decreased exposure of the Con A 
receptor to the aqueous environment (Shinitzky and Inbar, 1976). 
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The opposite conditions can also exist. An increase in the mobility 
of the Con A receptor in normally associated with decreases in the 
"fluidity" of the lymphocyte cell membrane (Shinitzky and Inbar, 
1976). 
The tricyclic antidepressants do not alter the mobility of the 
Con A receptor as monitored by the fluorescence polarization of F-
Con A. Observations of any fluorescence polarization changes of F-
Con A in these experiments could be duplicated in aqueous solutions 
of F-Con A only, suggesting a significant interaction between 
tricyclic antidepressants and F-Con A. It should be noted that the 
tricyclic antidepressant concentrations that alter the polarization 
of F-Con A were 100-1000 fold greater than those concentrations of 
tricyclic antidepressants that altered the fluorescence anisotropy 
and lifetime of DPH, and inhibited lymphocyte mitogenesis. These 
results suggest that the tricyclic antidepressants do not alter the 
mobility or exposure of the Con A receptor of the murine splenic 
lymphocyte. 
The absence of a relationship between the tricyclic 
antidepressant binding site apparent and concentrations which 
inhibit lymphocyte mitogenesis is not unique. The murine lymphocyte 
also possesses a propranolol binding site of high affinity (10 nM) 
but propranolol concentrations that inhibit lymphocyte mitogenesis 
are 1000-fold higher (Audus et al., 1983). The effects of 
propranolol at the concentrations higher than the apparent for 
the binding site are probably attributable to the local anesthetic 
properties of propranolol (Audus et al., 1983). Similarly, the 
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tricyclic antidepressant effects on the murine lymphocyte at 
concentrations much higher than the k<j for the binding site, could 
be attributable, at least in part, to local anesthetic properties of 
the tricyclic antidepressants. Concentrations of tricyclic 
antidepressants that produce membrane perturbations, as monitored by 
DPH fluorescence, can also alter the function of membrane associated 
proteins in a manner that is partially reversible. The ecto-ATPase 
of leukocytes which may play a role in regulating membrane 
permeability is inhibited by 0.1 to 1 mM concentrations of 
tricyclic antidepressants and related phenothiazines (Medzihradsky 
et al., 1980). Further, this ecto-ATPase is not sensitive to other 
pharmacologically active agents such as phenobarbital, morphine, 
amphetamine, and phenelzine (Medzihradsky et al., 1980.), suggesting 
that there are, possibly, specific drug-protein or drug-membrane 
interactions required to produce inhibition of ecto-ATPase. This 
evidence, along with the results of our study, would suggest that 
the tricyclic antidepressants may alter normal cell processes by not 
only perturbing the structural integrity of the cell membranes but 
also perhaps by altering the function of membrane associated 
proteins. 
In summary, the results suggest a possible relationship between 
the concentrations of tricyclic antidepressants that inhibit murine 
lymphocyte mitogenesis, and the concentrations of tricyclic 
antidepressants that perturb the structural order of the murine 
lymphocyte membranes. As determined by fluorescence spectroscopy, 
tricyclic antidepressants perturb the lymphocyte membrane in a 
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dose-, time- and temperature- dependent manner that is consistent 
with membrane effects produced by agents with known local anesthetic 
properties. In other experiments using a fluorescent probe for Con 
A receptors, results suggest that the tricyclic antidepressants do 
not alter the mobility or exposure of the Con A receptor. 
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EXPERIMENTAL STUDIES 
PART V 
TRICYCLIC ANTIDEPRESSANT DRUG EFFECTS 
ON LIPOSOMAL MEMBRANES 
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ABSTRACT 
Tricyclic antidepressant drug:liposomal membrane interactions 
have been characterized by using a fluorescent probe, 
diphenylhexatriene (DPH). The tricyclic antidepressants used in 
this study (nortriptyline, protriptyline, imipramine, and 
desipramine) can be placed into two groups based on their 
interactions with DPH labeled liposomes. 1) Nortriptyline and 
protriptyline were found to induce lipid bilayer perturbations in 
liposomes composed of 67 mol% dipalmitoyl-phosphatidylcholine (DPPC) 
and 33 mol% dioleoyl-phosphatidylcholine (DOPC). Perturbations of 
DPPC + DOPC liposomal membranes, as monitored by the fluorescence 
anisotropy and lifetime of DPH, are concentration- and temperature-
dependent. Effects of nortriptyline and protriptyline on DPH 
fluorescence anisotropy or lifetime in DPPC, DOPC, or egg yolk-
phosphatidylcholine (egg PC) liposomes could not be established. 2) 
Desipramine and imipramine quench the fluorescence emission of DPH 
in DPPC + DOPC and egg PC liposomes. The concentrations of 
imipramine and desipramine that quench DPH fluorescence emission in 
DPPC + DOPC liposomes are similar to the concentrations 
nortriptyline and protriptyline that perturb the lipid bilayers of 
DPPC + DOPC liposomes. Desipramine and imipramine do not alter the 
fluorescence anisotropy or lifetime of DPH in DPPC liposomes, but do 
quench the fluorescence emission of DPH in egg PC liposomes. 
The size of the liposomes was assessed by electron microscopy 
and range from about .1 to .8 urn in diameter. 
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INTRODUCTION 
A growing body of evidence suggests that alterations of 
membrane lipid structure may be an important mechanism by which 
hormones and other small molecules regulate cell function (Rasmussen 
et al., 1981; Hirata and Axelrod, 1980; Pilch et al., 1980; Goodman 
et al., 1975). The tricyclic antidepressants inhibit lymphocyte 
mitogenesis (Audus and Gordon, 1982; Nahas et al., 1979; Smith et 
al., 1978; Waterfield et al., 1978), reduce numbers of plaque 
forming cells (Smith et al., 1978), in vitro, reduce elevated 
rheumatoid autoantibody levels (Haydu et al., 1974) and produce 
leukopenia (Leyberg and Denmark, 1959) in vivo. Recent 
experimental evidence suggests that tricyclic antidepressant drug-
induced perturbations of membrane lipid structure may be related to 
tricyclic antidepressant-induced inhibition of lymphocyte 
mitogenesis (Audus and Gordon, 1984). 
Biological membranes are enormously complex, and therefore, it 
is very difficult to specifically characterize detailed molecular 
interactions between drugs and the phospholipid bilayer of 
biological membranes. Phospholipid vesicles or liposomes, 
represent relatively simple models of the phospholipid bilayer of 
the biological membrane that can be used to characterize lipophilic 
drugrmembrane interactions (Bangham, 1978: Tritton et al., 1977). 
In this paper, we describe tricyclic antidepressant drug 
effects on the structure of large multilamellar liposomes prepared 
from DPPC, DOPC, and egg PC. 1,6-Diphenyl-1,3,5-hexatriene (DPH), a 
highly lipophilic fluorescent probe (Shinitzky and Barenholz, 1974), 
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has been used to characterize the concentration and temperature 
dependence of drug induced alterations of liposomal membrane 
structure. The size of the multilamellar liposomes was determined 
by electron microscopy. 
MATERIALS AND METHODS 
l,6-Diphenyl-l,3,5-hexatriene (DPH; lot no. 2021A) was 
purchased from Molecular Probes, Inc., Junction City, OR. 
Imipramine hydrochloride (lot no. 121F-0086), L-a-
phosphatidylcholine dipalmitoyl (DPPC), and L-<x-phosphatidylcholine 
dioleoyl (DOPC) were obtained from Sigma Chemical Co., St. Louis, 
MO. Egg L-a-Lecithin (egg PC) was obtained from Avanti Polar-
Lipids, Inc., Birmingham, AL. Desipramine hydrochloride was a gift 
from Merrell Dow Pharmaceuticals, Inc., Cincinnati, OH. 
Nortriptyline hydrochloride was a gift from Lilly Research 
Laboratories, Indianapolis, IN. Protriptyline hydrochloride was a 
gift from Merck Sharp & Dohme Research Laboratories, West Point, PA. 
All other compounds used in this study were of the highest grade 
commercially available. 
Liposome Preparation. An appropriate aliquot of phospholipid, 
from a 20 mg/mL stock in chloroform, was placed in round bottomed 
nitrogen purged, stoppered-test tube. The chloroform was evaporated 
off with a gentle stream of nitrogen, and the phospholipid 
resuspended in phosphate buffered saline (PBS; pH 7.4). The 
phospholipid mixture was then heated to at least ten degrees above 
the transition temperature for the respective lipid and shaken by 
means of a vortex rotamixer for 5 niinutes. To the resulting 
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suspension of large multilamellar liposomes, an equal volume of PBS 
containing dispersed DPH was added to a final phospholipid to DPH 
ratio of about 500:1. The final concentration of phospholipid is 
approximately 0.1 |ig/ml. The liposome mixture was incubated at 
room temperature for 45 minutes and used immediately for 
spectroscopic measurements at 37 ̂  unless otherwise indicated. 
DPPC(67 mol%) + DOPC(33 mol%) were prepared by adding 
appropriate amounts of each phospholipid to the same round bottomed 
test tube. The remainder of the preparatory procedures for DPPC + 
DOPC liposomes were as described above. 
Drugs were dissolved in either PBS or distilled water and added 
to liposome suspensions (sample) in aliquots of 1 to 30 u.1 with 
Hamilton microliter syringes. Addition of either PBS or distilled 
water in equal amounts, and at similar times, to a liposome 
suspension served as the corresponding control. Unless otherwise 
indicated, sample and control liposome suspensions were incubated at 
37 °C for 5 minutes prior to measurement of fluorescence anisotropy 
or lifetimes. 
Following the protocol of Bangham and Home (1964), liposomes 
for electron microscopy were prepared in a similar manner, except 
that the liposomes were prepared in distilled water to a final 
concentration of approximately 5 mg/ml. Equal volumes of the 
liposome suspension and 2% potassium phosphotungstate in water were 
mixed for 30 sec. A drop of the stained liposome mixture was placed 
on a cellulose carbon grid, the drop drained, and after drying, 
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examined with a JEOL-100S electron microscope at instrumental 
magnifications of 40,000 to 100,000. 
Steady-State Fluorescence Anisotropy Measurements. 
Instrumentation has been described in detail previously (Audus et 
al., 1983; Audus and Gordon, 1984). Briefly, measurements were 
made with an SLM 8000 interfaced with a Hewlett-Packard 87 computer 
for on-line data acquisition and analysis. The fluorometer was set 
up to measure fluorescence anisotropy 
r = (A - B) / (A + 2B) 
where r is anisotropy. A is the ratio of the fluorescence 
intensities parallel and perpendicular to the plane of polarized 
excitation light with the excitation polarizer in the vertical 
position. B is the ratio of the fluorescence intensities parallel 
and perpendicular to the plane of polarized excitation light with 
the excitation polarizer in the horizontal position. The sample was 
excited with 360 nm light and emission monitored at 430 nm. 
Light scattering due to turbidity of the liposome suspension 
was found not to be significant at the phospholipid concentrations 
used in these experiments. The tricyclic antidepressants absorb DV 
light maximally around 250 nm, and therefore the fluorescence of the 
tricyclic antidepressants did not contribute significantly to the 
fluorescence of DPH labeled liposomes. The temperature of the 
sample cell was controlled by a circulating water bath and the 
contents of the sample cuvettes stirred with a magnetic stirrer. 
Fluorescence Lifetime Measurements. Methodology and 
instrumentation for determination of fluorescence lifetimes has been 
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described elsewhere (Audus and Gordon, 1984; Lackowicz, 1983). 
Briefly, fluorescence lifetimes were calculated from phase and 
modulation measurements made with an SLM 4800 subnanosecond 
fluorometer interfaced with a Hewlett Packard 87 for on-line 
acquisition and analysis. The phase shift and the modulation of 
each sample was measured alternately 4 times, with the time interval 
between each measurement of about 10 sec. Data was acquired by the 
interfaced computer, averaged and the lifetimes calculated from the 
following basic relationships: 
V a s e = V w t a n G 
Tmod. - <Vw) (W - l ) 1 / 2 
where T p h a s e is the phase lifetime, 0 the phase shift in degrees 
caused by a sample of lifetime T, w is the angular frequency of 
excitation which is 2 * pi * modulation frequency (30 MHz), T m o a e 
is the modulation lifetime, and D is the ratio of 
Mfluorophore ^reference' w h e r e M represents the relative 
modulation of a reference solution. 
The sample was excited with 360 nm light and emission from the 
sample monitored through a KV-389 cut on filter. Lifetimes were 
determined in the presence of a reference fluorophore with a known 
lifetime (dimethyl-POPOP, 1.45 nsec). A rhodamine quantum counter 
solution was placed in the reference chamber and emission monitored 
through a RG630 filter. The contents of the sample cuvettes were 
stirred continuously with a magnetic stirrer and the temperature of 
the sample chamber controlled by a circulating water bath. 
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RESULTS 
Figure 1 illustrates the nortriptyline and protriptyline 
induced decreases of DPH fluorescence anisotropy of DPH labeled 
DPPC (67 mol%) + DOPC (33 mol%) liposomes. Nortriptyline and 
protriptyline do not alter the fluorescence lifetime of DPH in DPH 
labeled DPPC + DOPC liposomes except at very high concentrations (1 
irM). The fluorescence anisotropy of DPH in the DPPC + DOPC 
liposome suspension receiving only PBS (control) remained at 0.151 
+/- .004 during these experiments (data not shown). Nortriptyline 
and protriptyline did not alter the fluorescence anisotropy or 
lifetime of DPH in egg PC liposomes at concentrations of 10 ~? to 
1 0 ( n o t shown), or DOPC and DPPC liposomes at 1 0 M as shown in 
Table I. 
The four tricyclic antidepressants used in these experiments 
do not induce concentration-dependent alterations of either the 
fluorescence anisotropy or the fluorescence lifetime of DPH in DPPC 
liposomes. Figure 2 illustrates the inability of desipramine or 
protriptyline to alter the fluorescence anisotropy of DPH in DPPC 
liposome suspensions. The fluorescence anisotropy of DPH in a 
control suspension of DPPC liposomes remained at .337 +/- -001 
during these experiments. 
In Figure 3, data are presented which demonstrates desipramine 
and imipramine induced decreases of the fluorescence lifetime 
(phase) of DPH in DPPC(67 mol%) + DOPC (33 mol%) liposomes. The DPH 
fluorescence phase lifetime of a control liposome suspension 
remained at 7.75 +/~ 0.07 nsec during these experiments. Desipramine 
187 
and imipramine concentrations of 10" 7 to 10 "^M do not alter the 
fluorescence lifetime or anisotropy of DPH in DPPC liposomes (not 
shown). The fluorescence lifetime is decreases and the fluorescence 
anisotropy of DPH in egg PC liposomes with increasing concentrations 
of either desipramine or imipramine. Figure 4 illustrates the 
effect of increasing concentrations of imipramine, after a 3 h 
incubation period at 37 °C, on the fluorescence anisotropy of DPH in 
egg PC liposomes. The DPH fluorescence anisotropy of a control 
liposome suspension remained at .0648 +/~ «001 during these 
experiments. 
100 U.M (50 mol %) of either nortriptyline or protriptyline 
shifts the temperature dependent changes of the DPH fluorescence 
anisotropy in DPPC + DOPC liposomes to lower temperatures. Figure 5 
presents the typical temperature transition profile of DPPC + DOPC 
liposomes in the absence and presence of either protriptyline or 
nortriptyline. The fluorescence anisotropy of DPH in these 
liposomes is decreased by an average of approximately .025 
anisotropy units throughout the transition phase (20 °C to 40°C) of 
the liposomes. 
Figure 6 is an electron photomicrograph of a representative 
sample of DPPC (67 mol%) + DOPC (33 mol%) liposomes. The 
multilamellar liposomes range from .1 to .8 u.m in diameter. 
DISCUSSION 
Understanding the mechanisms by which small molecules such as 
drugs alter cell function through interactions with the cell 
membrane is a fundamental problem in pharmacology. The liposome 
188 
Figure 1. Effect of Nortriptyline and Protriptyline on the 
fluorescence anisotropy of DPH in DPPC (57 mol%) + DOPC (33 mol%) 
multilamellar liposomes. The fluorescence anisotropy value of DPH in 
a control liposome suspension remained at .151 +/- .004. 
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TABLE I 
Temperature Dependence of the Fluorescence Anisotropy of DPH 
in DPPC or DOPC Liposomes. 
DPPC Liposomes 
Additions 
+PBS 
+10"^ M Protriptyline 
+10"^ M Nortriptyline 
25°C 37°C 
.342 +/- .001 .317 +/- .001 
,340 +/- .001 .307 +/- .001 
.343 +/- .001 .312 +/- .001 
50 °b 
.089 +/- .002 
.089 +/- .001 
.088 +/" .001 
DOPC Liposomes 
Additions 
+PBS 
+10"^ M Protriptyline 
+10^ M Nortriptyline 
25°C 37°C 
.097 +/- .001 .071 +/" .001 
,097 +/" .001 .073 +/- .001 
.094 +/" .001 .071 +/" .001 
50°C 
.053 +/- -002 
.053 +/- .002 
.054 +/- .001 
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Figure 2. Effect of Desipramine and Protriptyline on the 
fluorescence anisotropy of DPH in DPPC (67 mol%) + DOPC (33 mol%) 
multilamellar liposomes. The fluorescence anisotropy value of DPH 
in a control liposome suspension remained at .337 +/~ .001. 
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Figure 3. Effect of Desipramine and Imipramine on the fluorescence 
phase lifetime of DPH in DPPC (67 mol%) + DOPC (33 mol%) 
multilamellar liposomes. The fluorescence lifetime of DPH in a 
control suspension of liposomes remained at 7.75 +/- 0.07 nsec. 
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Figure 4. Effect of Imipramine on the Fluorescence Anisotropy of 
DPH in Egg PC Multilamellar Liposomes. The fluorescence anisotropy 
of DPH in a control suspension of egg PC liposomes remained at .0648 
+/- .001. 
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Figure 5. Temperature Dependency of the Effects of Nortriptyline 
and Protriptyline on the Fluorescence Anisotropy of DPH in 
DPPC (67 mol%) + DOPC (33 mol%) Multilamellar Liposomes. 100 uM 
nortriptyline (+), 100 jiM protriptyline (o), and an equal amount of 
PBS (control, x), was added to DPH labeled multilamellar suspensions 
and the fluorescence anisotropy recorded at 2.5 degree intervals. 
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Figure 6. Electron Micrograph of DPPC (67 mol%) + DOPC (33 mol%) 
Liposomes. Liposomes were prepared as described in Materials and 
Methods section and observed at an instrument magnification of 
50,000x. 
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provides a useful model of the biomembrane*s phospholipid bilayer, 
enabling one to study, more directly, drug.phospholipid bilayer 
interactions (Bangham, 1978; Tritton et al., 1977). This study was 
conducted to determine the ability of the tricyclic antidepressants 
to alter the lipid structure of liposomes as monitored by the 
fluorescence lifetime and anisotropy of DPH. 
The fluorescence anisotropy of DPH in liposomes is interpreted 
in terms of changes in the structural order of the phospholipid 
bilayer (lackowicz et al., 1979; Lackowicz and Prendergast, 1978a; 
Lackowicz and Prendergast, 1978b). Increasing temperatures, for 
example, result in a decrease of the DPH fluorescence anisotropy of 
DPH labeled liposomes (Andrich and Vanderkooi, 1976). The decrease 
in the DPH fluorescence anisotropy may be interpreted as a decrease 
in the structural order of the lipid microenvironment of the DPH 
molecule. In the presence of decreasing temperatures (Andrich and 
Vanderkooi, 1976) or increasing hydrostatic pressure (Lackowicz and 
Thompson, 1983), DPH fluorescence anisotropy in the liposome, 
increases. This may be interpreted as an increased ordering of the 
lipid microenvironment of the DPH molecule. An increase in the DPH 
fluorescence anisotropy may also be due to quenching, and therefore, 
measurement of fluorescence lifetimes, which decrease as a result of 
some types of quenching, is used to interpret fluorescence 
anisotropy measurements (Lackowicz, 1983). 
As observed in the lymphocyte membrane (Audus and Gordon, 
1984), desipramine, imipramine, nortriptyline, and protriptyline can 
be placed into two groups based on their effects on the fluorescence 
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anisotropy and lifetime of DPH in the DPPC (67 mol%) + DOPC (33 
mol%) liposome. Nortriptyline and protriptyline effect 
concentration-dependent decreases in the DPH fluorescence anisotropy 
of DPH labeled DPPC (67 mol%) + DOPC (33 mol%) liposomes and have no 
significant effect on the fluorescent lifetime of DPH. In contrast, 
desipramine and imipramine produce a concentration-dependent 
increase in the fluorescence anisotropy of DPH in DPH labeled DPPC 
(67 mol%) + DOPC (33 moll) liposomes. However, the increase in 
fluorescence anisotropy of DPH caused by desipramine and imipramine 
can be explained in terms of quenching, since both imipramine and 
desipramine produce a concentration-dependent decrease in the 
fluorescence lifetime of DPH. The quenching of DPH fluorescence by 
desipramine and imipramine is probably due to intermolecular 
collisions (dynamic quenching) because 1) there is no spectral 
overlap between DPH and desipramine and imipramine, and 2) the 
quenching is temperature dependent (greater at higher temperatures), 
suggesting dynamic diffusion-dependent mechanisms. 
Protriptyline and nortriptyline induced decreases in DPH 
fluorescence anisotropy in DPH labeled DPPC (67 mol%) + DOPC (33 
mol%) liposomes are interpreted as drug-induced perturbations of the 
phospholipid bilayer. Desipramine and imipramine, on the other 
hand, do penetrate the DPPC (67 mol%) + DOPC (67 mol%) phospholipid 
bilayer and perhaps localize in the proximity of the excited DPH 
molecule resulting in the quenching of DPH fluorescence emission. 
It is probable that desipramine and imipramine, like protriptyline 
and nortriptyline, also perturb the phospholipid bilayer of DPPC (67 
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mol%) + DOPC (33 mol%) liposomes. Calorimetric, ESR, and NMR 
studies have demonstrated that desipramine and imipramine perturb 
the phospholipid bilayer of DPPC liposomes (Bermejo et al., 1975; 
Cater et al., 1974; Bermejo et al., 1974). 
In order to characterize the effect of the tricyclic 
antidepressants on the temperature transition profile of DPPC (67 
mol%) + DOPC (33 mol%) liposomes, 100 |iM of either nortriptyline or 
protriptyline was added to DPPC (67 mol%) + DOPC (33 mol%) liposome 
suspensions. The typical temperature transition profile of DPH 
labeled DPPC+DOPC liposomes in the absence of drug is consistent 
with the findings of Lentz et al. (1976b), However, addition of 
nortriptyline or protriptyline to DPPC (67 mol%) + DOPC (33 mol%) 
liposomes shifts the temperature transition profile to the right. 
These results are consistent with the understanding that molecules 
which perturb the lipid bilayers of liposomal and biological 
membranes, lower the transition temperature of the lipid bilayer 
(Cater et al., 1974). 
In our studies we were unable to demonstrate lipid structure 
perturbations in DPPC liposomes at a concentration of 100 (iM (50 
mol%) of any of the tricyclic antidepressants. This in contrast to 
calorimetric studies where desipramine produced lipid structural 
alterations in DPPC liposomes at 2 mol% (Cater et al., 1974). Cater 
et al. (1974) studies indicated that the lipid structural 
perturbations originated at the polar-head groups of the 
phospholipid bilayer. In such case, DPH may not be sensitive to 
changes in the fatty acid chain adjacent to the polar-head groups. 
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Moreover, desipramine and other tricyclic antidepressants may not 
readily penetrate to the fatty acids regions of DPPC liposomes due 
to the physical state of the lipid (gel) below the transition 
temperature (T m 41°C). 
Lower concentrations (<100uM or 50 mol%) of desipramine and 
imipramine produced an increase in the fluorescence anisotropy and a 
corresponding decrease in the fluorescence lifetime of DPH in egg PC 
liposomes. Nortriptyline and protriptyline, by comparison had no 
effect on the fluorescence lifetime or anisotropy of DPH in egg PC 
or DOPC liposomes. Since the quenching of DPH requires that 
desipramine and imipramine localize in close proximity to the 
excited DPH molecule, these results suggest that desipramine and 
imipramine must diffuse into the fatty acid domains of egg PC 
liposomes. The fatty acid chains of DOPC (Tm-20°) and egg PC 
liposomes are less tightly packed due to the presence of double 
bonds. Consequently, the lecithin bilayers of the DOPC and egg PC 
liposmes are much less ordered than DPPC bilayers. In this study 
high concentrations of (>50 mol%) nortriptyline and protriptyline 
are not apparently capable of perturbing the bilayers of the less 
ordered DOPC and egg PC liposome bilayers to a greater degree than 
they already are. 
DPPC, DOPC, and DPPC + DOPC liposomes have been well 
characterized with DPH fluorescence (Stubbs et al., 1981; Lentz et 
al., 1976a; Lentz et al., 1976b). It is interesting that 
concentrations (<50 mol%) of tricyclic antidepressants that perturb 
DPH labeled bilayers of DPPC (67 mol%) + DOPC (33 mol%) liposomes 
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did not perturb DPH labeled bilayers of either DPPC or DOPC 
liposomes. Since DPPC and DOPC are immiscible in both small 
vesicles and large multilamellar liposomes (Lentz et al.r 1976b), it 
is possible that the tricyclic antidepressants perturb DPPC (67 
mol%) + DOPC (33 mol%) bilayers at interfaces between lipid phases. 
An alternative explanation might be that the tricyclic 
antidepressants may access DPH labeled-DPPC (67 mol%) + DOPC (33 
mol%) bilayers through less ordered DOPC domains where permeation 
of the drug is less restricted. Concerning this latter point, there 
is a correlation between liposome permeability and the presence of 
unsaturated hydrocarbon chains (Demel et al., 1972). 
The DPPC (67 mol%) + DOPC (33 mol%) liposome is probably not an 
adequate model of a more complex biological bilayer. However, the 
formation of separate lipid domains, as in the DPPC (67 mol%) + DOPC 
(33 mol%) liposomes, may represent lipid-lipid relationships 
characteristic of some biomembranes (Klausner et al., 1980; Cullis 
and DeKruijff, 1979; Jain and White, 1977; Lentz et al., 1976b). 
The fact that tricyclic antidepressants interact differently with 
DPPC (67 mol%) + DOPC (33 mol%) liposomes (Fig. 1, 3, and 5) than 
with DPPC or DOPC liposomes (Fig. 2 and Table I) may indicate how 
lipid-lipid relationships affect drug.cell membrane interactions. 
The apparent octanol/water and octanol/buffer partition 
coefficients of the tricyclic antidepressants used in this study are 
significant and quite similar from one compound to another (Frisk-
Holmberg and Van der Kleijn, 1972; Leo et al., 1971). Therefore, 
similarity of the concentration- and temperature- dependent 
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alterations in the fluorescence lifetime and anisotropy of DPH 
labeled bilayers is not considered unusual. 
Recent studies indicate that tricyclic antidepressant-drug 
induced down-regulation of central beta-adrenergic receptors may be 
related to the clinical effects of the tricyclic antidepressants 
(Richardson and Hertz, 1983; Sulser, 1982). Effects, in vitro, of 
tricyclic antidepressants on beta-adrenergic ligand binding to 
murine astrocytes are observed at micromolar tricyclic 
antidepressant concentrations (Richardson and Hertz, 1983). Since 
micromolar amounts of tricyclic antidepressants perturb the 
liposomal membrane, similar tricyclic antidepressant drug-induced 
perturbations of the murine astrocyte membrane may be relevant to 
beta-adrenergic receptor subsensitivity. Liponomic control of 
proteins has been suggested as a possible mode of action for the 
action of some small molecules on biomembranes (Rasmussen and 
Matsumoto, 1982). 
The results of our study indicate that the tricyclic 
antidepressants, nortriptyline and protriptyline, perturb the DPH 
labeled bilayers of DPPC (67 mol%) + DOPC (33 mol%) liposomes but do 
not perturb the DPH labeled bilayers of DPPC, DOPC, or egg PC 
liposomes. Nortriptyline and protriptyline induced perturbations of 
the bilayers of DPPC + DOPC liposomes occur at concentrations that 
are similar to concentrations of nortriptyline and protriptyline 
perturbed lymphocyte membranes (Audus and Gordon, 1984). In 
addition, nortriptyline and protriptyline decrease the transition 
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temperature of the lipids in DPPC (67 mol%) + DOPC (33 mol%) 
liposomes. 
In contrast, desipramine and imipramine quench the fluorescence 
emission of DPH in DPPC + DOPC and egg PC Liposomes at 
concentrations similar to those concentrations of desipramine and 
imipramine that quenched DPH fluorescence emission in murine 
lymphocytes. The concentrations of desipramine and imipramine that 
quench DPH fluorescence are also similar to the concentrations of 
nortriptyline and protriptyline that perturb the phospholipid 
bilayers of liposomes and lymphocytes. Other methods will be 
required to determine the presence of desipramine and imipramine 
effects on the lipids of DPPC (67 mol%) + DOPC (33 mol%) liposome 
and lymphocyte membranes. Finally, desipramine and imipramine do 
not alter the fluorescence anisotropy or lifetime of DPH in DPPC 
liposomes. This finding is not consistent with previous studies of 
the effect of desipramine and imipramine on liposomal membrane 
structure. 
The large multilamellar liposomes used in this study were sized 
by electron microscopy and range from about .1 to .8 (im in diameter. 
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SUMMARY AND CONCLUSIONS 
Initial experiments were conducted to determine if a specific 
tricyclic antidepressant binding site was present on the lymphocyte 
membrane. Prior studies had indicated that the tricyclic 
antidepressants were capable of altering lymphocyte function and 
growth both in vivo and in vitro. The mechanisms involved in 
alteration of lymphocyte function and growth, though, are poorly 
understood. Results from the experimental study herein describe a 
specific, saturable, high affinity tricyclic antidepressant binding 
site on the lymphocyte. The binding of tricyclic antidepressants to 
the high affinity binding site was also competitive, reversible, and 
does not display characteristics of cooperativity. The existence of 
the high affinity binding site suggested a possible mechanism by 
which tricyclic antidepressants might alter lymphocyte function. 
The second experimental study was conducted to determine if the 
high affinity binding site possessed biological activity. The 
ability of the tricyclic antidepressants to modulate mitogen 
stimulated murine lymphocytes was assayed. Concentrations of 
tricyclic antidepressants that inhibited mitogenesis were about 1000 
fold greater than the apparent affinity constant for the tricyclic 
antidepressant binding site. These results suggested that the 
specific tricyclic antidepressant binding site is not involved in 
the inhibition of mitogenesis. This does not preclude the 
possibility that the binding site may be involved in a biological 
function not associated with mitogenesis. Results from additional 
experiments demonstrated that the tricyclic antidepressants inhibit 
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mitogenesis when added to mitogen stimulated lymphocytes at various 
times up to 24 hours after initiating the cultures. 
Other drugs such as beta-adrenergic antagonists have high 
affinity binding sites on the murine lymphocyte and also inhibit 
mitogenesis at concentrations much higher than the apparent affinity 
constant of the binding site. The inhibition of mitogenesis by 
these drugs at high concentrations have been attributed to the 
ability of the compounds to perturb the lymphocyte's membrane 
structure. These perturbations are often referred to as "quinidine-
like" or local anesthetic effects. It has been presumed that the 
high concentrations of tricyclic antidepressants perturb membrane 
structure in a similar fashion. However, experimental evidence in 
biological membranes to support these assumptions has not been 
reported. 
The third and fourth experimental studies were conducted to 
provide experimental evidence that membrane perturbations at high 
concentrations of either beta-adrenergic antagonists or tricyclic 
antidepressants are involved in the inhibition of lymphocyte 
mitogenesis. The ability of a compound to perturb bicmembranes is 
associated with lipophilicity of the respective compound. Since the 
tricyclic antidepressants possess very similar apparent organic 
solvent/aqueous partition coefficients, it was desirable to include 
in this study a class of compounds with a range of different 
apparent organic solvent/aqueous partition coefficients. The beta-
adrenergic antagonists were found to be suitable for this 
investigation based on the range of apparent partition coefficients. 
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Results of the third experimental study indicate that 
concentrations of beta-adrenergic antagonists that perturb 
lymphocyte membranes are similar to those concentrations of beta-
adrenergic antagonists that inhibit lymphocyte mitogenesis. 
Further, beta-adrenergic antagonists with high partition 
coefficients perturbed lymphocyte membranes, while beta-adrenergic 
antagonists with very low partition coefficients did not alter 
lymphocyte membrane structure. By comparison, beta-adrenergic 
antagonists with high partition coefficients inhibited lymphocyte 
mitogenesis in a concentration-, time-, and temperature- dependent 
manner, and beta-adrenergic antagonists with low partition 
coefficients had little or no effect on lymphocyte mitogenesis. 
Results of the fourth experimental study demonstrate that, like 
the beta-adrenergic antagonists, concentrations of tricyclic 
antidepressants that perturb lymphocyte membranes are similar to 
those concentrations of tricyclic antidepressants that perturb 
lymphocyte membranes. Perturbations of the lymphocyte membrane, by 
tricyclic antidepressants are concentration-, time-, and 
temperature- dependent. The concentrations of each of the tricyclic 
antidepressants necessary to perturb lymphocyte membranes and 
inhibit lymphocyte mitogenesis were similar and consistent with the 
fact that the apparent partition coefficients for these tricyclic 
antidepressants are also similar. 
In a final series of experiments, the ability of the 
tricyclic antidepressants to alter liposomal membranes was 
determined. Since the biological membrane is extremely complex, 
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specific information about drug:phospholipid bilayer interactions 
can not be determined. The liposome provides a simpler model of the 
biological membrane phospholipid bilayer which can be used to 
investigate specific drug phospholipid bilayer interactions. In 
previous studies, low concentrations of tricyclic antidepressants 
were shown to perturb the polar-head groups of dipalmitoyl-
phosphatidylcholine (DPPC) liposomes. Interestingly, the specific 
fluorescent probe diphenylhexatriene, used in the studies herein, 
was not sensitive to DPPC or DOPC bilayer perturbations induced by 
lower concentrations of tricyclic antidepressants. However, low 
concentrations of tricyclic antidepressants that were effective in 
perturbing the bilayers of DPPC + dioleic-phosphatidylcholine (DOPC) 
(2:1) liposomes were similar to the concentrations of tricyclic 
antidepressants that perturb lymphocyte membranes. The results also 
indicate that lipid:lipid interactions may be important in how a 
drug affects the phospholipid bilayer. 
To conclude, these studies demonstrate tricyclic antidepressant 
drug:lymphocyte membrane interactions at very low concentrations 
with a specific tricyclic antidepressant binding site, and at higher 
concentrations with, presumably a non-specific binding site, the 
phospholipid bilayer. Lymphocyte responsiveness, as monitored by 
the lymphocyte mitogen response in vitro, was found to be unaffected 
by tricyclic antidepressant interactions with the specific tricyclic 
antidepressant binding site. Other studies, however, demonstrated 
that inhibition of the lymphocyte mitogen reponse may be related to 
the ability of these drugs to perturb the lymphocyte membrane 
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structure. Mditional studies in model membranes support the 
assumption that lymphocyte membrane perturbations by the tricyclic 
antidepressants originate in the lipid domains of biological and 
liposomal membranes. Studies of the non-specific effects of the 
beta-adrenergic antagonists showed that inhibition of the mitogen 
response of lymphocytes may related to beta-adrenergic antagonist 
induced perturbations of lynjiiocyte membranes. Concentrations of 
beta-adrenergic antagonists that interact with the specific beta-
adrenergic bindings site do not alter the lynphocyte mitogen 
response. Finally, evidence from these studies shows the importance 
of non-specific drug:membrane-̂ dependent interactions that may 
contribute to the understanding of the biological activity of these 
two classes of drugs. 
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